Anyone can take charge of their own health and learn the limitations of Coumadin. Some decide to continue it and gradually expand their protection, since Coumadin is totally inadequate for any real protection while starting things like Garlic, Ginkgo, Fish oil etc, all as found in Beyond Chelation Improved.

Blood clots DO kill many each year; in fact, some believe that most heart attacks and even strokes are the result of blood clots. If true, then blood clots would be nearly the leading cause of death. Yet, in spite of this known risk, I usually rely on entirely natural approaches and I take my patients OFF Coumadin. I do not like the minimal benefits and the substantial risks documented with Coumadin therapy.

Most patients within a few days or weeks on just Beyond Chelation-Improved feel enough subjective improvement that they usually elect to stay on the product. However, with the increasing burden of toxins and infections in the population, those that can afford it are also told to take Bolouke or Nattokinase twice a day in addition to their daily dose of BC-I.

I believe that labs like ThromboCare in Dallas can help protect you by finding some of the proven genetic problems contributing to the epidemic of HYPERCOAGULABILITY that I feel sets the stage for MI and Stroke. Those tests often conclude that standard anticoagulant approaches will be inadequate to benefit the patient. And that leads to complex protocols using toxic drugs and many patients elect to assume full personal responsibility and bet their lives on natural products.

Of course, I repeat that BC-I does provide a SAFE HEPARIN-like action because EDTA makes heparin and related sulfated mucopolysaccarides provide benefits from simple oral administration. This makes BC-I with Bolouke or Nattokinase an extremely attractive alternative to patients who understand that many will require anticoagulation therapy for many years.

Some who have read everything on the subject spend $500-1000 and get a Hemex test while on Coumadin, just to prove to themselves that the head of the American Heart Association, Dr. Valentin Fuster, in his book “Vulnerable Atherosclerotic Plaque” was correct when he said that Coumadin, Heparin, and Aspirin are all inadequate!

We have found some really tough cases who need to be on very aggressive NATURAL product based anticoagulant programs even though using just my basic program of Beyond Chelation Improved, 1 pack twice daily (9 pills in each pack), and Wobenzym, 5 twice daily has been enough so far that we have not heard of anyone in the thousands taking the program in the past 20 years having a heart attack or a stroke.

The good news is we simply do not see heart attacks or strokes in those who follow the program, so we know, after doing this for 20 years that we are really onto a basic new way of practicing preventive medicine. However, of course, we are not God so the more testing and actual knowledge of a patient’s condition we have, the more there are other things that we might want to recommend.

We have many with heart valves and some who felt poisoned from the first day of taking Coumadin, who have decided to be my patients so have chosen to take a different approach to staying alive. So far, we have been extremely successful. The $10 million of research by Dr. Lester Morrison proves we are on the right path, but we are not a drug company, and thus, this approach is NOT covered by any insurance.

However, we deal with very sick patients and in some cases we also need to use some Heparin injections (or oral troches) until they have lowered their chronic infection load. Also, with the increasing pollution today, I often add to that 9 pill packet, which has Primrose and Omega 3 and Garlic and Ginkgo etc, taken twice a day Lumbrokinase (Boluoke) or Nattokinase, the first is stronger and more expensive. I find that Boluoke from Canada is a very incredible alternative to Coumadin, although it retails around $2 per capsule. The dose is two- three times a day or 3 twice a day taken on empty stomach, preferably at least 45 minutes before a meal and at bedtime.

So, for tough patients with serious problems, like chronic fatigue, Fibromyalgia, Cancer, autoimmune diseases, arthritis, disabling Migraine, serious hypertension, heart valves, or who may have a history of lung clots, leg clots, early heart attacks, etc., I also prefer to go even further than just my very successful basic program and use extra Essential Daily Defense 2 with each meal. This is our basic EDTA, containing a Garlic blood thinning formula, as found in Beyond Chelation Improved, and chelator of heavy metals that I believe everyone needs to take at least 6 every day of their life.

Since some see me as the father of chelation therapy, this is perhaps my biggest contribution by making some of the important detoxification and blood thinning benefits of chelation therapy available at home, orally and affordably for everyone, no matter what else they are taking. Even if they are on Heparin and Coumadin and aspirin, this works mildly and broadly and has no contraindications. After all, eating Szechwan food also thins the blood and we do not make you stop going out for hot spicy Chinese food just because you are on Coumadin!

You still have some freedom to think and act for yourself, although even taking vitamin E affects your test results when you are on Coumadin; the issue is why not learn what natural things affect your test results and decide if they make more sense than blindly following your doctors’ advice to take rat poison every day of your life. Read up on Coumadin then decide what you want to do for your health. This is an opportunity to learn something that in the long run, I am convinced, will add years to your life!

All this is on my website, www.gordonresearch.com but you now know more you’re your average cardiologist! So, either you let them do what they want because that is all they know, or you choose to take charge and bet your life that there is another way.

Sincerely,
Garry F. Gordon, MD,DO,MD(H)

Dr. Gordon’s Suggested Protocol for Coumadin, Plavix and Aspirin Alternatives



Medical Applications of Zeolites (PDF)

from “Handbook of Zeolite Science and Technology”

One-Minute Push of Calcium EDTA

The 1-minute straight IV push method of administration of CALCIUM EDTA has been safely used in Europe for over 30 years. Doctor Blumer near Zurich, Switzerland has given tens of thousands of these without adverse effect and followed his patients for up to 30 years afterward. He has reported an unbelievable 80-90% reduction in the incidence of heart attacks and cancer in his patients who took at least 30 of these. These pushes may be given 2-3 times a week when the patients’ need for detoxification is greater, or monthly when they are being primarily given for preventive purposes.

We have physician colleagues that have taken over 2000 IV’s of 3 gram dosages, at the slow 1.5 – 3 hour rate which has been the primary method of administration of EDTA in the United States. I recommend that my patients should understand that the proven benefits and the minimum risk associated with the clinical use of EDTA suggests that if they feel the benefits from these IV pushes, they may safely plan to continue to use these IV push treatments preventatively for as long as they want, but probably less frequently once their primary health problem has been resolved.

We have all seen or heard about dramatic benefits in some patients receiving the old slow IV EDTA infusions. Now I have been hearing those stories and more from physicians following the basic simple protocol I am proposing here. And we are hearing about even more dramatic success stories from the physicians that I work with who are going ahead and developing more complex and specialized protocols to be used in the treatment of advanced complex diseases.

By starting with this basic approach you will be amazed at the clinical responses you will be seeing in your patients and be interested in attending more conferences and sharing with your colleagues ideas that arise out of this affordable and convenient new application of IV EDTA. Since the 1-minute push is painless and takes so little time, the opportunity exists to offer other IV therapies during that same visit, depending of course on the patient’s
needs.

This 1-minute application hopefully might even finally induce all of the health practitioners offering this wonderful heavy metal detoxification technique to REGULARLY do this for themselves as well as their families and staff. .

I assure you that based on the compliments I get everywhere I go that you will look and feel so much better that your patients will just ask to do whatever YOU are doing for YOUR health. This way there is no need to sell the benefits of effective heavy metal detoxification to your patients. They will ask for it and the provocative urine and fecal mineral tests appropriately done I assure you routinely find such elevated levels in virtually every patient, that they want the treatment described in this protocol now, and that documentation in your chart protects you and your medical board regarding any charges of over utilization etc.

However your diagnosis is NOT lead poisoning EXCEPT when the report really reveals levels way above the levels you will discover in all of us. I suggest the diagnosis is that you have “evidence of increased body burden of toxic metals,” that in your professional opinion, is not in the best interest of the patient in attempting to meet their stated health goal. SEE urine and fecal testing guidelines on my website.

In other words, patients with arthritis, cancer, asthma, autism etc. all deserve to receive PHYSICIAN SUPERVISED ELECTIVE HEAVY METAL DETOXIFICATION, but if you call this “poisoning”, you will
have to be prepared one day to defend that diagnosis in court. The lead industry and all other polluters have their “experts” just like the cigarette industry had. You will need to have LOTS of experience and special knowledge to warrant third party reimbursement for this treatment on your patients if you plan to use a diagnosis of either toxicity or metal poisoning, since the polluting industries can safely argue that most of us are enduring this level of mercury etc in our bodies, and in their eyes this has nothing to do with health. Of course I am convinced that these “average” levels are lowering the vitality and health of everyone on earth.

I am concerned that the substantial benefits and remote risks associated with the routine ingestion and most health professionals or the public they serve simply do not understand administration of EDTA. Calcium EDTA is about as safe and costs about the same as Vitamin C. I am convinced that I can rationally argue that EDTA should today be seriously considered to be a conditionally essential nutrient for those desiring optimal health while living on a polluted planet. Therefore, my position is that all of us seriously underutilize EDTA by for example not taking it orally every day, since it provides so many health benefits in every condition through its non- controversial and readily provable detoxification effects. See my website for 500 + PUBLISHED ABSTRACTS from mainstream literature documenting the detoxification benefits of oral EDTA.

I suggest that patients should not plan to stop the oral chelation nor the IV pushes, even after they have seen all their symptoms go away; this includes normalizing blood pressure levels, increasing energy, relief of vague non-specific symptoms, etc. that patients on this program routinely enjoy. EDTA based heavy metal detoxification, augmented with other oral chelators including garlic, which actually helps remove mercury from the brain, helped by malic acid and dl Methionine are a basic part of my approach to every chronic degenerative disease. The other ESSENTIAL parts of my approach are correcting the hypercoagulability and lowering the microbial load. If you learn to address all THREE of these issues concurrently, there is virtually no patient that you cannot significantly help. We have two well known 90+ year old CHELATING physicians who have personally taken over 2000 IV chelations in their lifetime. They appear 20+ years younger than their chronological age. This conclusively has convinced me that there is little possibility of ever overdoing EDTA therapy. The Intravenous CALCIUM EDTA that I use is available from Apothecure Pharmacy in Dallas, TX. A common package size provides 30 mg vials and each cc contains 300 mg. (twice as concentrated as the old Disodium EDTA we have used in the past)

This is given through a 23-gauge butterfly infusion needle and usually we simply take an empty disposable 10 cc plastic syringe and give the CALCIUM EDTA directly in the vein with this syringe without any dilution. This is administered over 10-120 seconds. (LONGER is permissible, as you have to feel comfortable, and some still prefer to put this in some solution and infuse it to time.) Some may add other IV therapies, before or after the administration of the EDTA push, at the same visit, depending on the other therapy and the reason it is being given, it may more advantageously be given after the other therapy.

The dose is 50 mg per Kgm body weight so a 70 Kgm person might get up to a 3.5 Gm dose but since it has been documented to provide such profound benefits at the 2-3 gm dosages, we actually rarely give over 3 Gm per person (10 cc); and for long-term maintenance dosages, excellent results are reported in Europe with just 1.5 to 2 Gm (5 – 6.66 cc) when given by this direct IV push method. I tend to try and use the higher permissible dose when doing the provocative test, which should ideally be done on either the first or second treatments. Sometime a small dose of 1.5 Gm on the first visit allays the patient’s concerns and then you can do the provocative with the highest permissible dose on the second visit. I generally use the largest permissible dose because I am training Physicians and patients on the first or second IV push to look at this new technique as a provocative test, like looking at the oil dipstick on your car to see how dirty the oil has become. The hair test is useful for screening purposes, but this IV push really uncovers substantial toxicities not seen on hair, as the exposure may have been some time ago.

Subsequently, if, as is the case with a few elderly weak or low body weight patients, they inform you that their first push where you gave the full dose, perhaps 3 Gm., made them a little weak for a few hours, there is no real need to stay at that higher level, so plan to reduce to as little as 1.5 GM. However, as they detoxify over the first 5-30 of these IV pushes, we find that generally they can easily tolerate the higher doses. This, of course, is not to exceed the dose that they are eligible to receive based on the 50 mg per Kgm dose rule, and depending on renal status. Thus, never hesitate to use the lower doses of 1.5 to 2 Gm dosages for ANY Reason, following the first provocative test. We have learned from Dr. Blumer’s experience in Switzerland that most of the dramatic LONG-TERM benefits of reduced heart disease and cancer are achieved in his patients with as little as 1.5 to 2 Gm., although he felt somewhat more confident of routinely achieving the full benefits at the 2 Gm dose.

I believe however, that we have become so toxic today, that those whose weight warrants and who clearly tolerate well the dose of 3 Gm, as 98% seem to, should receive that full dose for the extra detoxification effect. I also must report that I have had dramatic success in patients who can not or will not take the IV’s and instead of worked with me on higher doses of oral EDTA, such as the over 6 GM daily by mouth I have been on now for 6 + months, and over 2 Gm daily for years. (as in 15 Essential Daily Defense) The parenteral dose of EDTA must be somewhat lower in patients that have known renal insufficiency. I have long ago carefully spelled this out in what is now known as the ABCT/ ACAM protocol, that I originally wrote almost 30 years ago, and has been SAFELY used on over 1 million patients. We know that about 1 in 100 chelation patient may see some decreased renal function with parenteral EDTA chelation, although I am not aware that this has ever been reported with oral EDTA. However, it seems clear that if the lower doses are adhered to, and adequate time between infusions (or pushes) is given, we actually have shown the reversal of renal insufficiency with EDTA so commonly that we have come to virtually routinely expect to document evidence of improving renal function in 99% of cases treated as outlined in the protocol. We have even successfully administered IV EDTA to patients that were on dialysis and some of these patients no longer need dialysis.

Nonetheless, living in a litigious society, good medical practice requires some type of informed consent in treating patients in anyway that is even slightly “off label”. In other words, you are now using EDTA for its FDA approved purpose of treating increased body burden of toxic metals as revealed on laboratory tests. However, since the rapid administration was not routine in the US, you need to inform your patients that in the United States, most EDTA has been only administered by slow infusion. I suggest you can explain that this 11/2 – 3 hour treatment has been extremely useful to the over 1 million patients who have received IV Chelation therapy under the old ACAM protocol that I originally wrote, and certainly many physicians may wish to continue to offer that method that we all have become so accustomed to.

However our deteriorating environment along with the increasing recognition of the adverse effects on our health of even the “average” levels of toxic metals that we are all routinely exposed to today, makes me convinced that we now will find even more advantageous for our patients, particularly in many non cardiovascular related conditions, to also offer EDTA using the rapid 1 minute approach. This is because we can readily document vastly augmented detoxification benefits over anything ever seen with the slower 1-3 hour approach, or even with other available, often more toxic and clearly more expensive, chelators. We can prove this in almost any patient by sending a fecal and a 6-hour urine mineral test off after the old method of chelation and then repeating these two tests a few days later using my new oral EDTA product, combined with 1-minute IV EDTA technique. The resulting dramatic increase in toxic metals seen in urine and feces using this protocol will astound and convince you.

This new approach is documenting excretion of toxic heavy metals coming out in levels never seen before with any method of administration or any other chelator currently available anywhere. It still remains to be determined if the 1-3 hour Disodium EDTA Chelation method may still have some superior anti-aging or other benefits. I believe it is possible that it may be somewhat more effective in certain conditions and those doing well with that approach may still see additional benefits if they occasionally do the rapid IV method for its enhanced detoxification effects.

I could theorize that the parathormone induction is very beneficial in some conditions, potentially in osteoporosis. This induction is only possible with the slow IV use of DISODIUM EDTA, which however, is so painful for some patients that many have given up chelation entirely, to their own great detriment. Clearly Disodium EDTA MUST continue to be given slowly, and since many will want to continue because it has helped so many patients, we can look to the outcome of major studies currently planned for Disodium EDTA to help us determine its proper place. I always believed that this slow IV administration method provides enhanced benefits for our patients where we knew we were dealing with various aspects of metastatic and pathologic calcium accumulation. Now, however, the research about nanobacteria and pathologic calcification being treated with rectal suppositories and tetracycline may largely supplant the need for the slow IV drip of Disodium EDTA.

NOTE: I am convinced that rectal administration of CALCIUM EDTA is not better absorbed than orally administered EDTA. Therefore, unless it is artificially prevented from being excreted from the body, rectal suppositories should not be providing any benefits above those obtained with oral and rapid IV Calcium EDTA. It is claimed by some that they are seeing a higher blood level after many hours with their rectal suppositories, however, I prefer to maintain good blood levels of EDTA by taking small more frequent oral doses, so that the heavy metals EDTA attracts are not kept in the body, but are continuously being excreted. Perhaps the main indication for rectal suppositories is when the patient is unable to swallow or has an extremely sensitive stomach.

Unfortunately, since some patients failed to see reversal of their elevated coronary calcification levels as measured on E.B.T. (Electron Beam Tomography) or on coronary ultra fast cat scans with the old chelation technique as adopted by ACAM some 30 years ago, we now find a big interest in more effective approaches and certainly the work with rectal suppositories deserves careful consideration. There is always something more to learn and I prefer to use the oxidative therapies to the rectal suppositories in combination with this protocol, but there is a need to accumulate more data. The inability to reverse some coronary calcifications with the old protocol that I initially wrote, has put pressure on chelating doctors to broaden their approach to Cardiovascular disease and treat every associated risk factor vigorously, whether it is elevations of c-reactive protein, homocysteine of Lpa. This protocol is merely another step in helping to develop new protocols that can save at least some of the best and most predictable of the chelation benefits we have all seen in nearly 1 million patients, most of which I now suspect may have been due to improved NO (Nitric Oxide) induction, and not due to any roto-rooter effect or actual plaque removal.

Obviously with all of these potential considerations, we have to cover at least the relevant aspect of this for our prospective chelation patients planning to receive the rapid I minute IV push. Some of these patients may still be laboring under the belief that any form of chelation works essentially as a form of “Drano” and is cleaning their arteries. It is nice that many patients feel as though this must be happening when they can function so much better after a series of these. But as a procedure that arguably may be considered by some to be experimental, because we are not waiting for full-blown metal poisoning to develop, and therefore we are providing it as an elective procedure and we are giving it more rapidly than is commonly done in this country may well warrant your providing a full informed consent.

I recommend obtaining an informed consent for the protection of all involved, and I believe we must try to inform our patients as accurately as possible the benefits and potential risks. You should explain that detoxification can lead to increased NO and, therefore even though they may soon have more energy and be able to do much more physically, they may still have the 90% obstruction or more, in a major vessel than they started out with. This is confusing for patients who see their marked increase in exercise tolerance, and can not understand how they may at the same time look worse on their next arteriogram or heart scan, and some, particularly those who fail to stay on my effective natural anti-clotting therapies, which I build around oral chelation, may even sustain a heart attack or stroke. There are answers to every problem and we cannot cover all of molecular cardiology here, but for example, calcium pump in endothelial cells can not function effectively to pump calcium out of cells until fully cleared of all toxins. Furthermore, the chronic hidden infections that we all have, like chlamydia, CMV, nanobacteria etc. may require oxidative therapies and my chronic infection protocol.

Furthermore, there is a need to adequately address the subject of renal function and why monitoring is needed. After the successful safe treatment now of over 1 million patients with EDTA, is seems clear that I am not recommending these patients be required to have any creatinine clearance testing, unless there is some abnormality seen in other tests that require further evaluation. I believe in the interests of controlling medical costs, that a simple Urinanalysis provides enough information for monitoring most patients, unless there is a history of some known renal problem or previous abnormal renal function test then an occasional serum bun and creatinine.

We recognize that any renal testing related to chelation therapy, unless it is for DOCUMENTABLE metal poisoning cases, is not considered reimbursable by some insurance companies such as Medicare, since they feel the test is being done to monitor an uncovered experimental therapy. In this case, most of your patients will be choosing ELECTIVE heavy metal detoxification the same as they might choose to have plastic surgery. This logically makes any renal monitoring you order, UNLESS for other reasons, unrelated to their receiving EDTA, which reason must be documented in the chart, a non- reimbursable procedure for most patients.

We do not want to waste patient’s precious economic resources on low yield extensive renal tests, but since some forms of renal abnormalities are rampant in the population, good medical practice requires your good judgment on this critical issue. This is particularly in view of the probably somewhat incorrect or slightly misleading admonition in the old protocols that administration of EDTA slowly increased the safety for the kidneys. It now seems on reconsideration of this point, that since we have successfully chelated patients who were already on dialysis, that in fact, patients with compromised renal function automatically take far longer for the EDTA to clear, and the rate of administration is minimally if at all important in safety. Total dose and FREQUENCY of administration however appear to be important factors in potential for renal toxicity.

The new concept that I advocate of NEVER giving parenteral chelation with EDTA without concurrently providing oral EDTA is because oral EDTA is only 5-18% absorbed so the remainder can remain in the intestine where it is able to chelate any toxic metals presented through the bile and through the bowel/capillary interface by the IV EDTA. This oral EDTA then can trap and hold these toxins; largely eliminating the enterohepatic reuptake of these toxins that was apparently an unrecognized aspect of all parenterally administered EDTA. This enterohepatic reuptake was markedly decreasing the detoxification efficiency of all parenterally administered EDTA, now shown by the augmented excretion levels being seen in fecal tests on patients receiving concurrent IV and oral BROAD spectrum chelating agents as found in EDD (Essential Daily Defense). Remember, we seldom have only 1 metal present in excessive amounts and no single chelator adequately binds all the toxic metals that we are routinely finding on the Doctors Data reports.

Provocative Urine and Fecal Testing

I urge patients to get this test done on the first or at least by the second IV push. Of course it is best to obtain those measurements early on and to have them in the doctors chart for documentation that you were treated for elevated body burden of toxic metals as established by laboratory test. Today this is easy since the values seen are generally significantly elevated on one or more of the toxic metals on almost everyone living today on planet earth. Furthermore I look at this important provocative testing as providing useful and sometimes life-saving LAB information. The provoked urine and fecal mineral test is often more informative than a treadmill ECG, which test after all carries real potential for harm and the knowledge gained is far less useful in terms of patient outcome than what you will uncover with provocative mineral testing.

The urine is collected for 6 hours after the IV push (with 10- 15 oral caps of EDD) and carefully shaken before the aliquot is poured off and sent to Doctors Data and the next day a part of the next stool specimen can be submitted. This may be 18- 36 hours after the push was given. I prefer to do these tests for both toxic and essential minerals, since low excretion of essential minerals is a good indicator of deficiency, as in copper etc.

Fortunately there is NO record of any serious renal or other damage ever occurring from a single injection of EDTA that I am aware of from the over 7000 articles on EDTA that I have reviewed over the past 30 years. Based on my extensive experience with risk to benefit ratio on medical practices particularly involving chelating agents, I do NOT require more than a comprehensive Urinanalysis by dipstick to determine general renal status before doing this initial provocative test. Subsequent plans for giving 30 or more of these IV pushes over time will require occasional renal monitoring with BUN and Creatinine and based on history and physical, possibly even more intensive testing.

I believe with the levels of toxicity we are documenting in fecal and urine tests with this protocol may provide some of our patients, at least theoretically, with documentation making them potentially eligible for some possible legal action against various providers of these toxins, such as may exist with mercury and vaccines and or dentist exposures. Thus, our patients deserve to be shown accurately just how relatively toxic they are and I know of no way better than following this protocol and collecting URINE and FECAL material for testing to establish this information. Thus the maximal dose of EDTA for their body weight and renal status permits us to recover in the urine and fecal mineral tests the highest amount of toxic metals. This then indicates just how badly poisoned they really are, since we are all relatively toxic, and this information can help in your prognosis, as you will uncover some toxicities that until now you have not dreamed of. These toxic burdened patients are walking in and out of your offices with every form of general non-specific health complaint that may seem too non-specific to alert most of us to the contribution these heavy metals are making to our patients’ symptoms. The more carefully you can document these relatively more “poisoned” patients, the better some of those patients may be able to later collect if there is found a potential source for their toxicity and liability can be established.

There is no need today for the rather excessive level of renal monitoring that I felt forced to require of physicians 30 years ago using EDTA for what even today is still considered to be experimental purposes since then we were using EDTA for treatment of heart disease. We now have over 1 million safely treated patients’ data to rely on and we are NOW back to using the EDTA for FDA approved indications, i.e. treating increased lead, arsenic, mercury, cadmium and other heavy metal body burdens. Thus I believe, the frequency and type of renal monitoring should largely be left to the physician in charge of the patient, who is looking at benefit to risk issues, overall health issues, economic considerations, planned frequency of administration and even the medical condition for which treatment is being offered. For example, the literature makes it clear that chelation therapy for impaired renal functioning associated with low-level lead toxicity, particularly with elevated levels or uric acid, is almost predictably markedly improved.

Oral EDTA

The rapid IV EDTA treatment is leading to such dramatic outpourings of toxic metals including mercury that frankly, there is no other chelator with this degree of well-established safety and this amazing affordability available anywhere in the world that can compete with the successes we are seeing. The concurrent use of ORAL EDTA products such as ESSENTIAL DAILY DEFENSE (10-15 caps per day) further dramatically augments that effectiveness, as you will see for yourself in monitoring your patients urine and fecal tests, as well as the symptom improvements reported in a host of complex medical conditions. (Please see research on NO- (Nitric Oxide) and circulation, NO and Diabetes, NO and immunity, and then review old chelation literature.) This perspective will enable you to better understand the dramatic improvements in health from so many diverse conditions as are currently being reported by Physicians now utilizing this new use of an old therapy. Without understanding the importance of inducible NO and endothelial dysfunction, the reported benefits in so many seemingly diverse conditions would normally have to written off as unbelievable or at least ascribed to a powerful PLACEBO effect. Now the urine and fecal tests prove that something very basic is going on- effective heavy metal detoxification.

Please recommend 10 to 15 of the oral broad-spectrum chelator EDD, containing EDTA and other chelators such as Garlic, malic acid, dl methionine, etc. the day you give the IV push. The first dose can be 5 caps on arising or this even works if given as little as 2 to 4 hours before the IV and another 5 capsules again immediately when the IV push is given to help prevent any enterohepatic re-absorption of toxic metals. The third dose may be taken that evening, or even just 4 + hours after the IV push. Failure to concurrently administer ORAL chelators is markedly curtailing therapeutic effectiveness when providing chelation therapy for metal detoxification. Of course, I believe that common sense suggests that since oral chelators are extremely inexpensive, yet have well documented heavy metal detoxification benefits, patients should remain on these between IV’s, and possibly for life at lower maintenance levels.

ESSENTIAL DAILY DEFENSE, previously known as GARLIC PLUS, is a totally safe oral nutritional broad-spectrum detoxification and blood-thinning supplement. The FDA approved dose of the EDTA component in these capsules is 1000 mg per 35 pounds of body weight. Each EDD – Essential Daily Defense capsule contains 133 mg, thus the 10- 15 capsules daily dose recommended above with the push is conservative, and may safely be consumed continuously for years. Note: 15 capsules provide 2 GM of EDTA, which is really technically only an adequate dose for a 70-pound person, although since I plan to use this therapy long-term and we are not generally treating acute life threatening levels of toxic metals, this suffices. Technically, you could go considerably higher in the oral dose on the days the patient is not getting the IV push, I have found no need to use more aggressive oral doses as a routine. A guideline to for a Therapeutic level of Essential Daily Defense is 1 cap per 10 pounds; maintenance dosages are 1 cap per 20 pounds of body weight.

However, there is another case to consider, there are patients where the administration of IV `s may be impractical. For these cases, we need to try to accomplish a meaningful provocative test and offer this as an ORAL provocative challenge. In such cases we should plan to administer after calculating the full 1000 mg of EDTA dose for every 35 pound of body weight so that a 175-pound patient may now receive a full 5 gm of ORAL EDTA as a provocative test when they are not able to take the IV push. Taking that quantity of EDD is approximately 37 capsules and since that may seem to the patient to be difficult to take so many capsules we might also provide 3 gm of the dose as 1 level tsp of ORAL EDTA (pure powder in water or juice, pleasant tasting and easy to take) and the other 2 gm as 15 capsules of the EDD. This is because without the addition of EDD to the provocative test, we are not getting any of the necessary thiol groups (SH-as we now get from the organic hi potency garlic in the EDD) to broaden the spectrum of our oral provocative toxic metal challenge test and we would not see as much Mercury for example. Furthermore the malic acid component will pick up Aluminum and Iron, in some cases better than the EDTA.

For the patients receiving parenteral EDTA of any kind, the toxic heavy metals presented to the GI tract by the portion of the IV EDTA that does go through the liver and into the bile, is trapped and held in the intestine by the generally poorly absorbed oral EDTA, which in this case is an ADVANTAGE, since we want an effective chelator in the bowel at all times to catch the heavy metals presented by the liver, as well as to trap and hold any toxic metals we may be already consuming in our diet.

I tell my patients that choose to undergo elective physician supervised heavy metal detoxification that this is like plastic surgery, and is generally entirely elective, but here you do something for how you feel, not just how you look, I explain that I believe we were not intended to carry the high levels of toxic metals we are showing in virtually everyone tested as outlined above. If we do not plan to stay on some low level of oral chelation for life, these toxins will simply re-accumulate and the newly found high level of optimal health that this heavy metal detoxification program is giving, will again gradually be lost by the patient. Hopefully many will find it within their budget to also get perhaps monthly IV pushes to augment the benefits of the oral program.

Addendum Further information and useful reading about EDTA is available on my website at www.gordonresearch.com.

“Agreement for the Advanced Metal toxicology Protocol”

ICIM lecture, where the 250 slides can be reviewed will cover almost every conceivable question. Instatape taped the presentation I made in March 2002 for Physicians training for certification by the AMERICAN BOARD of Chelation Therapy (now renamed The American Board of Heavy Metal Toxicology). The 3-hour lecture that goes with the 250 slides on my website is available at 1-800-NOW-TAPE.

My lecture schedule can be found under my new PHYSICIAN’S RESOUCE JOURNAL, which you can subscribe to future editions by e-
mailing your request to me at newsletter@gordonresearch.com.

You may also join our email chelation discussion group on request.

The tape that explains much of this to your patients is called “Detoxification with new EDTA program. Steps to maximize
your health”. This is a 1-hour interview that was seen on public access TV in the Phoenix area by a chelation physician, Dr Bruce Shelton, who interviewed me. He has found that this videotape markedly increased his practice; copies may be made and loaned to your patients. The videotape is available at www.LongevityPlus.net (1-800-580-PLUS) for $10.00.

Garry F Gordon MD DO MD (H)
President, Gordon Research,Institute
www.gordonresearch.com

Original Paper

EDTA and Chelation Therapy: History and Mechanisms of Action, an Update

Garry F. Gordon, MD, DO, MD(H)

ABSTRACT

Twenty-four years have elapsed since my first article on EDTA, co-authored with Dr. Robert C. Vance first appeared. In the past 50 years, it is estimated that over one million patients have received intravenous chelation therapy with one widely used chelator, EDTA. Unfortunately, I believe we may have still failed to discover the primary mechanism(s) of action responsible for the frequently dramatic clinical improvements seen in numerous apparently unrelated conditions treated with EDTA and/or other chelators, unless it is simply that the binding and/or removal of toxic metals permits improved metabolic functioning in a variety of conditions. With science documenting the adverse effects of commonly encountered low levels of heavy metals on health, it is possible that chelation therapy is being vastly underutilized in standard medicine and that combinations of new and existing Chelating agents may need to be employed to deal with the broader spectrum of toxic metals now being identified as contributors to many if not most diseases, including aging.

INTRODUCTION

I am currently a medical consultant to two companies that are involved in food supplement sales and both of these companies sell oral EDTA containing products. Since my initial review of the available literature1 many more references to EDTA are now available. Unfortunately, today’s excessive focus on the potential benefits to patients suffering symptomatic cardiovascular disease has significantly, stifled the utilization of EDTA and other chelators in other conditions where I believe it should be routinely utilized, at least as an adjunct to other therapies. These indications include many common and difficult to treat conditions from acute rheumatoid arthritis and psoriasis, to cirrhosis of the liver and cancer, where clinical benefits have been described. I hope to refocus attention to the metal binding activity of chelating agents in general, so that this treatment may soon achieve its proper recognition as an adjunctive therapy in the management of many common health problems.

A BROAD VIEW OF CHELATION IN MEDICAL PRACTICE

Brain and renal function, diseases, macular degeneration, arthritis and arteriosclerosis,are all conditions that have been reported to show benefits from IV EDTA chelation. Over thirty documented mechanisms of action associated with the use of this form of chelation therapy have been published. Newer developments in molecular medicine and cell signaling suggest, however, that there may be other, far more important basic mechanisms waiting to be discovered. One of these might be regulation of transcription factor NFKappaß activity, which plays a pivotal role in immune dysregulation. The dramatic responses in some cases of rheumatoid arthritis in the literature may be explained with inhibition of Nfkappaβ by EDTA. This opens up many interesting possibilities for future chelation research in several seemingly unrelated conditions. Recent research in Alzheimer’s disease involves the cortical deposition of Abeta. This has been found to be completely reversible with zinc and copper chelation.

I believe that Chelation therapy for subclinical metal toxicity could soon become far more widely employed by many health care practitioners, many of whom probably will never become trained by either one of the organizations providing advanced training, or become fully certified by the American and/or the International Board of Chelation Therapy. There are many natural substances, including all weak organic acids, that are chelating agents and the public will undoubtedly soon begin self-treating with these various chelators as the health benefits of lowered levels of toxic metals becomes more widely appreciated. Accurate medical advice concerning oral chelating agents is essential. For example, research strongly suggests that cysteine-based oral chelators may, for example, re-deposit tissue-extracted mercury in the brain. Neither Chlorella, nor PCA (Peptidyl Clathrating Agent) significantly chelate mercury out of the body in spite of the claims. Garlic, on the other hand, appears to be generally beneficial and is documented to lower the level of lead in tissues, as well as to decrease platelet aggregability and demonstrate significant cardiovascular and anti-atherosclerotic benefits.

Chelators may also provide beneficial effects through their influences on other substances. For example, Morrison documented as much as 90% reduction in incidence of acute heart attacks, using his polysaccharide-based formula. By adding EDTA to his orally administered formula, we found that blood coagulability was reduced using the Chandler Loop test, (Gordon, GF, unpublished observation).

BYPASS VERSUS NEW IMPROVED COMPREHENSIVE CHELATION THERAPY

New developments focusing on the role of inflammation in cardiovascular disease clearly suggest that intravenous EDTA chelation therapy can no longer reasonably be considered as a primary or single complete therapy for the long-term management of cardiovascular disease.

Administration of IV EDTA offers many dramatic benefits including improved blood flow, and it deserves far greater recognition as a part of any comprehensive cardiovascular support program. With the recent recognition that some heart conditions have as much as a twenty thousand times increase in the level of some toxic heavy metals, chelation therapy, should be far more routinely employed. Some chelators believe that there is a worthwhile distinction between arteriosclerosis and atherosclerosis, which might improve treatment outcomes. They believe there is a higher content of calcium in the arteriosclerosis and a higher lipid content of the plaque seen in atherosclerosis. One of ACAM’s co-founders, David J. Edwards (written communication, October 14, 2000), has indicated that he is observing significantly enhanced benefits from IV chelation in the atherosclerotic patient by his addition of three lipolytic agents (choline, inositol, and methionine) to the IV treatment with the EDTA. Dr Edwards believes this treatment might be thought of as “lipid stripping” enhanced chelation. He feels that the primary benefits of EDTA is related to its primary metal-binding activity, and thus arteriosclerosis with its higher calcium content should be expected to have better results than atherosclerosis where the lipid problem must be separately addressed. He tries to distinguish between atherosclerosis and arteriosclerosis by the use of either rapid CT scan or soft tissue extremity x-rays.

I believe that IV EDTA Chelation therapy for cardiovascular disease should never be employed without concurrent aggressive effective pharmacological and/or nutritional/natural product based therapy for all the newly recognized applicable cardiovascular risk factors. These include replenishment of deficient minerals that become relatively even more deficient in the face of the serious excesses of toxic metals in heart muscle cells. Furthermore it has now become essential to deal effectively with the infectious and resulting hypercoagulability aspects reflected in the newer cardiovascular risk panels.

It is now established that about 85% of sudden cardio- and cerebro-vascular deaths are due to rupture of vulnerable, non-calcified arterial plaque and subsequent clot formation.28 This form of plaque, invisible by conventional angiography, initiates a terminal thrombo-embolic event superimposed on chronic vascular inflammation, hypercoagulation and metabolic derangement as in acquired homocysteinemia. Patients who choose I.V. chelation instead of by-pass surgery hope for more than symptomatic improvement, and when some learn that they still have seriously calcified coronary vessels on ultra high-speed cat scans, they are very disappointed. Some mistakenly opt for surgery at that time, even if they find they can easily sustain a far higher level of physical activity following their “unsuccessful” chelation therapy. Unfortunately most patients are unaware of the new information about Vulnerable Plaque, the kind that is actually now believed to be involved in heart attacks, and they are not told that this truly life-threatening plaque is not readily seen on any currently widely available vascular tests, including angiograms. This failure has led me to consider the standard vascular tests relied on to sell by-pass and other invasive procedures to patients, as, at the very least, unreliable and misleading. Improved oxygenation of ischemic tissues is a reasonable goal of therapy and simple improvement in exercise tolerance testing is very useful in evaluating this.

I believe that most patients seldom are adequately informed regarding the severe limitations of all surgical approaches in the management of their vascular disease. In fact, since the vulnerable plaque involved in 85% of heart attacks and strokes cannot be seen with modern technology, their heart surgery is generally attacking the wrong plaque and thus is providing little, if any, long term benefit at great expense and risk. It is now widely believed that the underlying cause of death in heart attacks and strokes is from a blood clot related to vulnerable soft plaque due to an active infection in the arterial wall, often caused by herpes related cytomegalic virus or chlamydia pneumonia. Current research calls for treating the blood to prevent these life-threatening clots, not the blood vessel.24

I hope that wider dissemination of this new information will help lead to the end of the largely useless surgical attack on coronary vessels so rampant today. In fact, some believe that operating on infected tissue is poor medical practice, which happens frequently with unstable angina as shown by elevated C-reactive protein levels that standard medicine has such difficulty managing. In fact, Dr Terry Haws has informed me that using the cardioCRP test offered by Quest Labs, that the majority of his new patients are coming back reported as “at risk” (verbal communication). It appears that just as “safe” levels of cholesterol and homocysteine tests, over time, were moved lower and lower, the same can be anticipated with c-reactive protein testing as more data regarding “ideal” values is accumulated. The infection that apparently we all have in our vascular tissues causes hypercoagulability, resulting in local ischemia that is far better treated medically. Of course, intravenous chelation always has a place in the management of any ischemic process. We all routinely expect to see improved circulation in 85% or more of our chelation patients and there are over thirty potential beneficial actions of EDTA to help explain this improved blood flow.

I believe that with our improved understanding regarding the need for effective control of hypercoagulability in virtually all ill patients, it may be beneficial to routinely add a more therapeutic level of intravenous or subcutaneous Heparin, along with more aggressive therapeutic levels of intravenous Vitamin C, in our efforts to manage this newly identified epidemic of hypercoaguability/infection related problems. 4,000 to 6,000 units of Heparin, based on weight, administered subcutaneously b.i.d. are safe, for a therapeutic trial of several weeks, without doing specialized coagulation studies in patients without a history of serious bleeding disorder (personal communication with David Berg, May 3, 2000). Longer term use of oral enzymes or daily heparin injections to decrease fibrinogen concentrations and soluble fibrin monomers appear to greatly facilitate the treatment of any chronic infectious process36.

Appropriate enteric-coated oral enzymes containing bromalain and/or heparin injections decrease fibrinogen concentrations and soluble fibrin monomers to facilitate the treatment of any infectious process. A safe approach in helping to combat infection can be with colostrum and colostrum-based transfer factor and other immune enhancing and cardiovascular supporting nutritional supplements. All are now better supported with a new, non-acidic, neutral pH, well-tolerated form of oral Vitamin C, and/or Vitamin C infusions. The already high efficacy of combinations of these natural approaches in dealing with any infectious process has recently been significantly enhanced by an effective extract of gram-positive bacteria known as muramyl polysaccharide glycan complex. This has been found to enhance immunity against all infections, and even shows anti-tumor activity.

We no longer have to rely on the long-term use of largely ineffective antibiotics alone for the control of chronic and often resistant infections now recognized in the hypercoagulability problem. Antibiotics alone have been shown to be inadequate for long-term control of chlamydia, although currently some experts are recommending a full year of azithromycin,35 or the other chronic hidden infections found in the vascular wall that is now clearly implicated in deaths from vascular disease.

I believe that the optimal use of EDTA in clinical practice needs to be totally repositioned, probably as an adjunct to most other therapies, providing improved management of most chronic diseases, since its primary function is eliminating excessive levels of metals. I fear negative outcomes from currently proposed and/or ongoing chelation cardiovascular studies where removal of the wrong plaque is the focus and the ethical dilemma in blinding any study may seriously jeopardize any studies. If, on the other hand, trace element studies are done to document the significant detoxification benefits seen with chelating agents, and long-term outcomes and quality of life data are compared to standard therapies, the combination of this data should offset any detected failure to simply remove plaque. Combined with safe, effective, natural treatment of all the newly recognized risk factors, such a comprehensive chelation protocol, I believe, would produce exceptional results. Since we have now entered the age of Einsteinian, molecular-based cardiology, nothing but the elimination of most by-pass surgery, a Newtonian concept, should be the goal.

Generally, the toxic metals removed by intravenous EDTA chelation simply start to re-accumulate once the treatment is discontinued. Thus, a number of oral chelators, including ascorbic, malic and lactic acids, may help maintain chelation benefits more cost effectively over a lifetime. Another approach is to reduce the biologic availability of heavy metals. For example, selenium binds mercury, markedly diminishing its potential for biologic harm, and many naturally occurring substances such as rutin and lactoferrin have been shown to have chelating properties. There is however, no single chelator available today that can effectively deal with the wide spectrum of potentially toxic metals that have been implicated in the degenerative diseases associated with aging. Thus, I believe that a broad spectrum of natural and/or pharmacological agents with chelating ability would be predictably more effective. My experience is that a comprehensive preventive approach can be effective even in high-risk patients, i.e. those with documented hi-grade involvement of two or three vessels.

For example, eicosapentaenoic acid supplementation, augmented with garlic, ginkgo, EDTA activated polysaccharides, bromelain and rutin can all be effectively employed synergistically in such a comprehensive broadly based protection program.

There is no critical need for monitoring with bleeding or clotting tests patients maintained on such a program since there is no significant risk of pathologic bleeding. It is, however, important to emphasize to the patient that this protection must be continuously maintained. Aspirin and NSAID’s reportedly contribute to over 16,000 deaths each year, largely as a result of induced G.I. bleeding. The benefits from aspirin and Coumadin are seriously limited24. The use of modern platelet aggregation and fibrinogen studies can show patients just how incomplete their standard drug protection is. By later repeating these tests after initiating a comprehensive natural product based anticoagulant program, patients can generally see the remarkably improved level of protection they now enjoy with little or no side effects.

The Homeopathic Medical Board of Arizona Chelation Peer review committee that I chair has currently advised physicians in Arizona that all chelation informed consent procedures for cardiovascular disease should specifically spell out the important caution that, even though patients may enjoy tremendous symptomatic improvement, actual (regular or visible) plaque reversal as measured and relied on today for prescribing life-threatening vascular surgery, may not be occurring.

BLOOD CLOTTING

Berg 38 has shown that a coagulation panel that is more sensitive than hitherto available is capable of distinguishing healthy from unhealthy subjects with over 95% accuracy. In fact, hypercoagulability is associated with a large number of chronic diseases.39

Since EDTA prevents clotting in blood collection tubes used daily, I believe more sensitive tests may show some subtle reduction of hypercoagulability. Possibly lowering the number of adhesion molecules, or soluble fibrin monomers, may be one of its subtler, but life saving benefits. The combination of a polluted environment, stressful life style and chronic low-grade infection leading to hypercoagulability, initially called the AntiPhospholipid antibody syndrome, has now more recently been renamed “immune system activation of coagulation” (ISAC). It appears to be surprisingly common and those at risk need long-term effective but safe lifelong anticoagulation treatment. Aspirin alone is too weak and too dangerous to handle this epidemic of hypercoagulability. It has also recently been reported to be too dangerous for men with hypertension to take on a regular basis. Effective aspirin substitutes include pancreatic enzymes (Wobenzym™) and properly stabilized bromelain supplements, preferably used in combination with garlic, Ginkgo, and salmon oil. A polysaccharide/ chelation based product, containing EDTA, also acts as an effective aspirin substitute and affordably helps to meet this nearly universal need.

ORAL EDTA

Chelating agents are routinely added to our food supply so that EDTA, for example, is added to foods for its ability to bind with the transition metals, particularly iron and copper. These agents inhibit rancidity in substances such as oils. This has led me to consider the potential benefits from the non-absorbed fraction of orally ingested EDTA, which, I believe, may help prevent oxidative degradation within the intestinal tract, just as phytic acid has been reported useful in chelating iron, which acts as a catalyst in the development of colorectal cancer. Many oral-chelating agents, including EDTA, might provide long-term protection, including helping to prevent potential intravascular coagulation. Remarkable responses have been attributed to various chelating agents, including DMPS, Penicillamine, Desferoxamine, as utilized by Paul Cutler (personal conversation, October 7, 2000) in the treatment of diabetes, infections and cancer and EDTA, in an extremely diverse number of conditions.

There are, in fact, over 300 references to the use of oral EDTA3. Nonetheless, there are many knowledgeable clinicians who are very negative about the oral ingestion of EDTA and who raise questions about its long-term safety. Recently published research has more than adequately rebutted those concerns.63, 64, I believe that the benefits of lowered levels of toxic metals and diminished availability of transition metals more than offsets any theoretical concerns about potential essential trace mineral depletion, about which I believe we have adequate knowledge to monitor and treat., and some research suggests that minerals become more bioavailable. Since only 5% of orally ingested EDTA is absorbed, taking 1200 mg for a year would provide at least some of the benefits seen from receiving 10 intravenous therapies of 3gm each a year.,

I am totally convinced that there are significant benefits from oral chelation for patients unable to undergo a more complete program of intravenous therapy, and further that oral EDTA helps provide for an effective maintenance program even for those who are concurrently undergoing a series of intravenous chelation treatments. Oral EDTA for the treatment of asymptomatic lead toxicity was FDA approved for the indication “to increase the excretion of lead.” This is described in the Physicians’ Desk Reference (PDR) through 1976, with obvious supporting references in the FDA files, complete copies of which we are still attempting to obtain. We, as licensed physicians, specializing in Chelation Therapy, I believe are fully responsible and probably legally liable to become adequately informed about the pro and con of all forms of chelation therapy, if we are to adequately discuss all of the available choices with our prospective chelation patients. This would seem essential if we hope to obtain a totally informed consent before prescribing chelation therapy for any reason, to our patients.

Oral EDTA probably exerts some anticoagulant and antiplatelet effects partially by the effect of chelating calcium ions. It has also been shown to prolong prothrombin time, and has effects on platelets, and other blood components, cell membranes and has cholesterol-lowering potential. EDTA has also has been the subject of a US patent because some therapeutic substances, especially sulfated polysaccharides, like heparin, which previously were only effective when given parenterally, became orally effective in the presence of EDTA.61 Oral EDTA therapy was discussed in the Waukegan News-Sun, because a soap manufacturer, Neil Purdy, was supplying EDTA powder to anyone who contacted him. A physician, Dr. James Mercer of Lenexa, Kansas, was favorably disposed to recommend this treatment to his cardiovascular patients. Dr. Mercer received a letter because of the improvement seen in a shared patient, from Dr. Sawyer, Professor of Surgery, State University of New York (written communication November 9, 1971) as well as a letter of support from Loren Parks, Director of Parks Electronics Laboratory, Cardiovascular Instrumentation of Beaverton, Oregon (written communication June 13, 2000). The oral EDTA therapy program recommended to those patients involved taking 3gm of sodium EDTA given in 6 ounces of preferably grapefruit juice or a Vitamin C drink. Additional mineral supplementation was advised for the patients. Dr. Mercer also reported a consistent lowering of cholesterol and triglycerides in the over 100 patients he treated with this regimen.

Studies have been published measuring urinary and fecal lead excretion induced by oral EDTA. However, the use of EDTA in the treatment of lead-poisoned workers fell into disfavor because of abuse by industrial-based physicians, who ignored the basic axiom of good medical practice, which is to remove as much as possible the source of exposure, rather than concentrating on the less expensive prescribing of oral EDTA tablets to lead workers. In spite of this, the PDR through 1976 under Riker continued to list calcium disodium Versenate tablets with the only approved indication, to increase the excretion of lead.

The body has many metal binding substances, including albumin, metalothioneins, ferritin, ceruloplasmin, transferin, and others. A reasonable hypothesis may be that additional chelators further support our health by enhancing our body’s ability to handle free metal catalyzed reactions. The reason that EDTA is routinely added to the food supply today is to help prevent the oxidative degradation of nutrients by chelating the transition metals. Our individual consumption of EDTA from food sources is estimated to average between 15mg-50mg per day. There has been concern raised that the widespread use of EDTA in our food may have an adverse effect on the environment because EDTA was non-biodegradable and may have increased the solubilization of heavy metals, particularly cadmium. Increasing low levels of EDTA in the environment may lead to the enhanced uptake of heavy metals, particularly cadmium, in living tissues. Fortunately, I believe we can neutralize this concern because cadmium had been shown to respond to adequate therapeutic administration of oral EDTA. EDTA has a 40-year history of oral use in asymptomatic patients with laboratory evidence of lead accumulation and can safely be given continuously in doses of up to 1gm a day to adults. Concomitant administration of essential trace elements, especially zinc, is obligatory. Its safety seems to be firmly established, and the potential of mineral depletion seems to be minimal.63,

In fact, at the NIH/ODS Bioavailability Conference the ENVIRON International Corporation report on mineral absorption listed EDTA as a dietary factor enhancing absorption and bioavailability of zinc along with protein, cysteine, citrate and methionine.

In a recent recorded and published interview by ACAM member and Diplomate of ABCT, Ron Kennedy, MD, of Santa Rosa, California, on the subject of oral chelation, I provided more of the historical background to further assist others in understanding some of the potential clinical applications of oral chelation.

The central role of iron in catalyzing free radical pathology, and consequently upon health span and longevity, belies the common clinical perception that iron saturation is preferable to the risk of deficiency. Epidemiological studies show that iron stores, as measured by serum ferritin, accumulate four times faster in males than pre-menopausal females and that cardiovascular disease is also four times more likely in age-matched men. Monthly menstrual iron losses may thus mitigate cardiovascular risks in a manner analogous with the chelation of excess free iron, inasmuch as hysterectomy, even with intact ovarian function, abolishes the protective effect. Similarly, regular blood donors show decreased incidence of myocardial infarction and cancer, recalling the Swiss experience with regular EDTA rapid IV injections of Calcium Disodium EDTA in carefully monitored patients over almost two decades. For example, the level of lead has now been shown to relate directly to IQ. This suggests that it would be prudent to offer some form of oral chelation to every student, recognizing the cost and importance of education in our society.

CHELATION AND HEAVY METALS

Chelation therapy benefits may still however be primarily the result of the obvious heavy metal detoxification. Blumer showed dramatic long-term benefits from parenterally administered calcium disodium edetate that clearly support the concept that we all may live far longer and healthier lives by simply decreasing our body burdens of lead. Occult lead intoxication has been documented to be a cause of hypertension and renal failure, and the disappearance of immune deposits in a patient with renal impairment due to low-level lead toxicity has now been demonstrated by renal biopsy before and after EDTA chelation. It has also been reported in one study that 4 out of 6 patients being treated for renal failure who developed gout de novo had underlying plumbism.

The future of combined chelation agents appears promising and largely understudied. The combined use of EDTA and DMSA shows clear advantages if the primary focus of therapy is identified- namely to reduce body burden of heavy metals such as lead. With lead toxicity still being an epidemic in the US, there is still no standardization in its therapy. Less than one-third of responding lead clinics report utilizing oral chelation as the agents of choice even though the 1984 consensus statements fully describe the use of penicillamine. Oral DMSA also appears to be safe and effective for the treatment of childhood lead poisoning. There is still no consensus regarding the use of provocative testing or protocols for treatment.

Olwin was one of the earliest investigators to recognize that blood flow improvement in vascular disease patients from EDTA chelation was very probably due to removal of lead. At that time, over twenty years ago, most experts were unwilling to accept this all too obvious explanation. This was partly due to our lack of understanding regarding the subtle adverse effects we are all suffering from as a result of the over 1000-fold increase in lead levels in average bone tissues today over pre-industrial levels. Since then, we have become much more knowledgeable about the magnitude of these increases in average lead levels and the adverse health effects associated with them. Research to document whether or not most chelation benefits are primarily from deleading effects alone, however, is complex and expensive. Furthermore, we cannot readily find a “control group” that is not significantly lead-burdened anywhere on our planet today. Experts now generally agree that there is no safe level of lead. This may make proving what chelation really does as complicated as that involved in documenting the adverse effects of second-hand smoke, from which virtually no one was truly escaping. Since everyone had some of the adverse exposure it was not simple to prove the long-term benefits of a smoke free, or in this case, a low lead internal environment.

Over the past twenty years, the so-called “safe levels” of all potentially toxic metals have gradually been lowered to the point that I believe that no one is escaping at least some of their adverse effects. This would suggest that everyone would have better health and respond better to the management of any disease process if we could safely and cost effectively assist them in controlling some of these toxic metals now seen in all living tissues. Therapeutic assistance might be either through simply increasing the capacity of the body to bind free metals safely, or by effectively removing them through some form of chelation therapy. We need to establish some standards for the responsible use of chelating agents. There are millions of children in the world suffering from sub-optimal health because of toxic metal overload. Upon finding at least a doubling of the excretion of a known toxic metal in a provoked urine specimen, compared to baseline tests, it would be reasonable to suggest some form of chelation, preferably oral.

We know that there are numerous published papers describing adverse effects with cadmium aluminum , mercury , iron and copper. Crapper-McLachlan has done extensive studies relating aluminum to the aging process. The mercury issue, thanks primarily to dental fillings, continues to wreak havoc on our health. With the public’s interest in anti-aging and detoxification, it appears reasonable that many will choose to detoxify themselves with whatever non-prescription chelators with which they become aware. We should be able to augment their efforts with knowledge and therapies they cannot self-administer.

Whenever possible, it makes good sense to remove the patient from a lead or other metal contaminated environment, but this is frequently not possible. Abuse of this principle by physicians working for the lead industry resulted in subsequent confusion regarding the benefits from the use of oral EDTA. They failed to follow the simple and basic principles of ethical medicine since nothing was done to clean up the workers’ environment. They chose instead to administer the inexpensive tablets of oral EDTA to the workers in order to maintain their blood lead levels in acceptable ranges, so they could continue working. Therefore, workers remained at risk on the job. This led to the American Medical Association condemning the use of oral EDTA in lead poisoned workers, although the tablets were FDA approved for treating asymptomatic lead poisoning, with the recommended dose of 1000 mg per 35 pounds body weight.

With increasing research documenting the danger of elevated iron levels, and the life-prolonging benefits associated with regular donation of blood, it is beginning to become quite clear that it may become malpractice to prescribe iron to patients without documenting their need. Many believe that it is the lower levels of iron that is primarily responsible for the increased life span of women over men. Research on a new oral iron-chelating agent under study shows dramatic benefits including protection against skin cancers, skin aging, ultraviolet protection and significant neural protection in trauma.

The initial observation of symptomatic improvement in chest pain in patients receiving EDTA for lead poisoning was coincidental. This led to many years of research on the effect of various chelating agents, whether administered orally or intravenously.

The many potential benefits from the chelating effects of toxic and transition metals have already been mentioned and we may come to realize that we have seriously under-utilized all forms of chelating agents in medical practice today due to our lack of appreciation of the tremendous increases in total metal burden we all face as a part of today’s environmental degradation. Current research regarding the adverse effects from our increased lead burden and the more recently recognized iron overload problem warrants every physician becoming knowledgeable in the appropriate use of oral and parenteral chelators and/or metal binding substances. It may not be necessary to completely remove a toxic or transition metal to obtain significant clinical benefits, as simply binding it, thus making it less available, may markedly diminish its potential for harm.

Experts in chelation chemistry (bio-inorganic chemists) such as David R. Williams have suggested that most health problem can be shown to involve a deficiency or excess of trace minerals at some level. The fact that Dimethylpropanyl sulfate (DMPS) was used by Russian investigators in the treatment of atherosclerosis and they reported and measured improved circulation I believe further suggests that the primary beneficial action from chelating agents is from reduction of our ubiquitous toxic metal burden, although life-extension benefits may be more directly related to the associated reduction in free radical pathology.

CALCIUM AND CHELATION

One of the paradoxes of aging is the occurrence of osteopenia in conjunction with vascular and soft tissue calcification, the precise cause of which is unknown. A deficiency of Vitamin K is an integral part of this undesirable pathologic calcification process. This is a complex process since coronary calcification is markedly increased in hostile young adults.

Nearly 90 percent of young dialysis patients have coronary calcification 2.5 to 5 times more than normal, raising serious questions about the current practice of aggressive calcium supplementation to offset the disturbed phosphorus metabolism in these patients. Those consuming the highest intakes of calcium revealed the most calcified vessels. Some of the worst levels were seen with associated elevations of c-terminal parathyroid hormone and this was also related to lower bone density.

Until effective prevention of this process becomes more widely available, the anti-aging benefits of chelation to reduce calcium content in vascular tissues remains highly desirable. However, it is clearly not a routinely predictable outcome. It should always be employed in association with the therapeutic modalities already discussed. After reviewing hundreds of radiograms before and after IV EDTA chelation, it is clear that grossly visible pathologic calcification is generally reduced, as I have seen on hundreds of before and after radiograms from the practice of Dr. Ray Evers (Gordon GF. Unpublished observation) even in nephrocalcinosis, calcinosis universalis, and Mönckeberg’s sclerosis. Extensive calcification of arteries was seen in radiographs of the 5,000–year-old “Ice Man” and in Egyptian mummies. Therefore, calcification of arteries is not a new disease. Sudden death from heart attack I believe is a modern, separate new, problem. The current research on hypercoagulation due to chronic inflammation may be a plausible explanation for how this is superimposed on arteriosclerosis.

AGING, LEAD AND OTHER HEAVY METALS

Davies showed that aging was associated with a gradual decrease in the levels of essential trace elements and a gradual increase in the levels of potentially toxic metals. Thus, chelation of heavy metals, together with replacement of essential elements is a logical step in the control of aging.

In considering the phenomena associated with aging, Tyler found that EDTA increased the life span of sea urchin sperm cells significantly by adding it to the seawater medium. The same kinds of results were observed in cells from roosters and steers. The decline of hormone levels with aging has been the subject of considerable interest, and much attention has focused on exogenous replacement strategies or attempts to re-stimulate endogenous secretion and release. Another potential benefit is suggested by the finding that lead lowers brain energy levels. Energy is essential for optimal health and the achievement of our maximum useful lifespan. Furthermore, Low-level lead exposure has recently been shown to speed up brain aging. Also the immune system has been shown to be more vulnerable to low levels of lead than other organ systems, leading to increased incidence of infectious disease and neoplasia. The ability of EDTA to remove low levels of lead and other toxic metals, which we might then expect to favorably influence immune, metabolic and endocrine function, appears to be worthy of further study. Oral DMSA has been found to chelate mercuric residues, and urinary recovery of mercury was shown to correlate with increased human growth hormone levels. The role of EDTA in the reversal of cross-linkages as a potential mechanism for the correction of biological aging was carefully reviewed by Carpenter. The dramatic life-span prolongation following EDTA exposure in prokaryotes and eukaryotic germ cells deserves further study as is the apparent improvement of general health commonly observed in humans from exposure to intravenous EDTA that may be partially explained by preventing or reversing the pathologic calcium accumulation seen in the aging of all mammalian cells.

Research indicates that a combination of several chelating agents offers significant anti-aging potential and EDTA may still find a major role in longevity medicine.

CONCLUSION

The potential contribution of chelating agents such as EDTA to the health of mankind can be greatly augmented as we begin to appreciate the wider implications of their basic detoxifying activity. We now have the unparalleled history of over 40 years of extensive and safe use of EDTA, with studies showing increasing life span in research models. Oral EDTA in our toxic world may become as essential for health as an essential nutrient, and it appears to offer potential benefits as diverse as those seen with some essential nutrients, suggesting we all carry a greater burden of toxic metals than is in our best interest for achieving either optimal health or our maximum intended useful lifespan. The completed human genome project will help us better appreciate human biochemical individuality so someday we may even know in advance which patients will have the more dramatic clinical improvements and apparent age-reversal that we have all seen in some of our patients with EDTA.

It is my belief that virtually everyone could benefit from the continuous lifetime ingestion of EDTA, and/or other chelators, to help offset the increasing burden of toxic and free metals coming from our degraded environment. By contrast, it has been proposed that 50 percent of the American public should be on lipid lowering drugs and the Pharmaceutical industry is seriously proposing that such medications become available over-the-counter so that the public can self prescribe these clearly not innocuous lipid lowering drugs. We must move toward evidence-based medicine. The skyrocketing costs of largely ineffective and soon unaffordable orthodox cardiovascular health care have been outlined in detail. I suggest that over-all health benefits from lowering toxic metals in everyone would far exceed those from administering statins to one-half of our population, with less risk, and less cost, since oral EDTA costs little more than vitamin C, and when combined with garlic would provide a broader spectrum of affordable chelation activity.22

Gordon GF, Vance RB. EDTA chelation therapy for atherosclerosis: history and mechanisms of action. Osteopath Ann, 1976;4:38-62.
Scharffenberg RS. Oral EDTA: A Bibliography. Carson City, NV: Vitamin Research; 1997.
Scharffenberg RS. EDTA Chelation Literature: Subject Index. North Hollywood, CA: American Academy of Medical Preventics; 1976.
Casdorph HR. EDTA chelation therapy: efficacy in brain disorder. J Adv Med. 1989;2(1/2)131-153.
McDonagh EW, Rudolph CJ, Cheraskin E. The effect of EDTA chelation therapy plus supportive multivitamin-trace mineral supplementation upon renal function: a study in blood urea nitrogen. J Holistic Med. 1983;5:163—171.
Riordon HD, Cheraskin E, Dirks M, Schultz M, Brizendene P. Another look at renal function and the EDTA treatment process. J Orthomolecular Med. 1987;2:185-187.
Kondrot ED. Healing the Eye The Natural Way. Carson City, NV: Nutritional Research Press; 2000
Boyle AJ, Mosher RE, McCann DS. Some in vivo effects of chelation—I: rheumatoid arthritis. J Chronic Dis. 1963;16:325-328.
Lamar CP. Chelation treatment of occlusive arteriosclerosis in diabetic patients. Angiol. 1964;15:379-395.
Godfrey ME. EDTA chelation as a treatment of arteriosclerosis. NZ Med J. 1990;93:100.
Boyle AJ, Mosher RE, McCann DS. Some in vivo effects of chelation—I: rheumatoid arthritis. J Chronic Dis. 1963;16:325-328.
Bowie AG, Moynagh PN, O’Neill LAJ. Lipid peroxidation is involved in the activation of NF-kappaβ by tumor necrosis factor but not interleukin 1 in the human endothelial cell line ECV304. Lack of involvement of H2O2 in NF-kappaβ activation by either cytokine in both primary and transformed endothelial cells. J Biol Chem. [National Library of Medicine online]. October, 1997;272(41):25941-25950
Mercurio F, Manning AM. NF-kappaβ as a primary regulator of the stress response. Oncogene [National Library of Medicine online]. November 1, 1999;18(45):6163-6171. Available from: Signal Pharmaceuticals, Inc, San Diego, CA
Ponnappan U. Regulation of transcription factor NFkappa B in immune senescence. Front Biosci. February 1,1998;3:D152-168.
Atwood CS, Moir RD, Huang X, et al. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem. May 2, 1998;273(21):12817-12826.
Quig D. Cystein metabolism and metal toxicity. Alternative Medicine Review. 1998;3(4):263-270.
Quig D. Metal Detoxification: a research based Update. Paper presented at: IOMA Conference, March 17, 2000; Westminster, CO.
Hanafy MS, Shalaby SM, El-Fouly MA, Abd el-aziz MI, Soliman FA. Effect of garlic on lead contents in chicken tissues. Dtsch Tierarztl Wochenschr. April 1994;010(4):157-158.
Lawson LD, Ransom DK, Hughes BG. Inhibition of whole blood platelet-aggregation by compounds in garlic clove extracts and commercial garlic products. Thromb Res. 1992 Jan;65(2);141-156.
Orekhov AN, Grunwald J. Effects of garlic on atherosclerosis. Nutrition. 1997 Jul-Aug;13(7-8):656-663.
Agarwal KC. Therapeutic actions of garlic constituents. Med Res Rev. 1996 Jan;16(1):111-124.
Koch HP, Lawson LD, eds. Garlic: The Science and Terapeutic Application of Allium sativum L. and Related Species.2nd ed. Baltimore: Williams & Wilkins; 1996.
Morrison LM, Schjeide OA. Arteriosclerosis: Prevention, Treatment, and Regression. Springfield, IL: Charles C. Thomas Publisher; 1984.
Morrison LM, Schjeide OA. Prevention and treatment of ischemic heart disease in human patients In: Coronary Heart Disease and the Mucopolysaccharides (Glycosaminoglycans): Springfield, IL: Charles C. Thomas Publisher; 1974:chap 10:185-224
Morrison LM, Enrick NL. Coronary heart disease: reduction of death rate by chondroitin sulfate a. Angiol. May 1973;24(5):269-289
Chandler AB. In vitro thrombotic coagulation of the blood: a method for producing a thrombus. Lab Invest. 1958;7:110.
Poole JC. A study of artificial thrombi produced by a modification of Chandler’s method. Q J Exp Physiol. 1959;44:377.
Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Eng J Med. March 23, 2000:836.
Fallon J, Libby P, Cornhill JF, Dinsmore R, Insull W. The Vulnerable Atherosclerotic Plaque: Understanding, Identification, and Modification. Fuster V, ed. Armonk, NJ: Futura Publishing Company; 1998.
Sullivan GW, Sarembock IJ, Linden J. The role of inflammation in vascular diseases. J Leukoc Biol [National Library of Medicine online]. May 2000;67(5):591-602. Available from: University of Virginia, Charlottesville, VA.
Kuvin JT, Kimmelstiel CD. Infectious causes of athersclerosis. Am Heart J. [National Library of Medicine online]. Feb, 1999;137(2):216-226. Available from: New England Medical Center Hospitals, Boston, MA.
Aldren H, et al. C-reactive protein testing: the importance of C-reactive protein testing in the prevention of heart attacks and strokes. Paper presented at: American College of Advancement in Medicine Evening of Innovation; October 28, 1999; Reno, Nevada.
Winslow R. Heart disease sleuths identify prime suspect: inflammation of artery. Wall Street Journal. October 7, 1999:A1.
Grier MT, Meyers DG. So much writing, so little science: a review of 37 years of literature on edetate sodium chelation therapy. Ann Pharmacotherapy. 1993;27:1504-1509.
Fox M. More evidence that infections cause heart disease. Science News [serial online]Available at: http://dailynews.yahoo.com/h/nm/20000918/sc/heart_bacteria_dc_1.html.
Hemex Laboratories. CFS/FM/MFP syndromes: a hypercoagulable state? Coag Capsule. Available at: www.hemex.com/cfs-fm-mfp_hyperstate.html. April 1, 1999.
Berg D, Berg LH, Couvaras J, Harrison H. Chronic fatigue syndrome and/or fibromyalgia as a variation of antiphospholipid antibody syndrome: an explanatory model and approach to laboratory diagnosis. Blood Coagulation Fibrinolysis. 1999;10:435-438.
Berg D, Berg LH, Ondreyco S, et al. Monitoring of heparin by soluble fibrin monomer generation in previously infertile women who became pregnant and carried their pregnancy to successful outcomes on heparin. Blood. 1997;90(10):111.
Reuters Health. Risk of aspirin for CHD prevention outweigh benefits in hypertensive men. BMJ [Medscape online] 2000;321:13-17. Accessed June 30, 2000
Chappell LT, Stahl JP. The correlation between EDTA chelation therapy and improvement in cardiovascular function: A meta-analysis. J Adv Med. Fall 1993;6(3):139-160.
Berg D, Berg LH, Couvaras J. Is CFS/FM due to an undefined hypercoagulable state brought on by immune activation of coagulation? Does adding anticoagulant therapy improve CFS/FM patient symptoms? AACFS Proceedings: Cambridge, MA. Octobert 10-12, 1998;62.
Engelberg H. Heparin and atherosclerosis. Monographs on Athersclerosis. 1978;8:1-72.
Klaschka J. Systemic enzyme therapy – improvement in the blood rheology. In: Oral Enzymes – New approach to Cancer Treatment: Immunology concepts for general and clinical practice: Complementary cancer treatment. Frankfurt am Main, Germany: Waldermar Kramer Publishers;1996:128-130.
Loimaranta V, Nuutila J, Marnila P, Tenovuo J, Korhonen H, Lilius EM. Colostral proteins from cows immunized with streptococcus mutans/S.sobrinus support the phagocytosis and killing of mutans streptococci by human leucocytes. J Med Microbiol. [National Library of Medicine online]. 1999;48(10):917-926. Available from: University of Turku, Finland.
Thomas IT, Soothill JF, Hawkins GT, Marshall WC. Transfer-factor treatment in congenital cytomegalovirus infection. Lancet. [National Library of Medicine online]. 1977;2(8047):1056-1057.
Viza D, Vich JM, Phillips J, Davies DAL. Use of specific transfer factor for the prevention or treatment of herpes infections in mice and in man. J Exp Path. 1987;3:407-420.
Dwyer JM. The use of antigen specific transfer factor in the management of infections with herpes viruses. In: Kirkpatrick CH, Burger DR, Lawrence HS, eds. Immunobiology of Transfer Factor. New York: Academic Press; 1983:233-242.
Aydin A, Ersoz G, Tekesin O, Akcicek E, Tuncyurek M. Garlic oil and helicobacter pylori infection. Am J Gastyroenterol. [National Library of Medicine online] February, 2000;95(2):563-564.
Salman H, Bergman M, Bessler H, Punsky I, Djaldetti M. Effect of a garlic derivative (alliin) on peripheral blood cell immune responses. Int J Immunopharmacol. [National Library of Medicine online]. September, 1999;21(9):589-597.
Ernst E. Cardiovascular effects of garlic (allium sativum): a review. Pharmatherapeutica. [National Library of Medicine online]. 1997;5(2):83-89. Available from: University of Munich, Germany.
Reynolds T, Dweck AC. Aloe vera leaf: a review update. J Ethnopharmocol. [National Library of Medicine online]. December 15, 1999;68(1-3):3-37. Available from: Jodrell Laboratory, Royal Botanic Gardens, Kew, Richmond, Surrey, U.K.
Qui Z, Jones K, Wylie M, Jia Q, Orndorff S. Modified alo barbadensis polysaccharide with immunoregulatory activity. Planta Med. [National Library of Medicine online]. 2000;66(2):152-156. Available from: Univera Pharmaceuticals, Inc, Broomfield, CO.
Riordan, NH, Meng X, Taylor P. Effects of cell wall extracts of gram positive bacteria (MPGC) on human immunity and tumor growth in animals. N Engl J Med. Paper presented at: Comprehensive Cancer Care, Center for Mind-Body Medicine, Jun, 2000, Arlington VA
Anderson JL, Muhlestein JB. The academic study in perspective (azithromycin in coronary artery disease: elimination of myocardial infection with chlamydia). J Infect Dis. [National Library of Medicine online]. 2000;181(suppl 3):S569-S571. Available from: University of Utah School of Medicine, Salt Lake City, UT.
Christensen K, Theilade D. EDTA chelation therapy: an dethical problem. Medical Hypotheses. 1997;10:69-70.
The Chemical Society London. Sillen LG, Högfeldt E, Martell AE, Smith RM, eds. Stability Constants. 2nd ed. Oxford, England: Alden Press; 1971;1(suppl).
O’Keefe JH Jr, Harris WS. From inuit to implementation: omega-3 fatty acids come of age. Mayo Clin Proc. [National Library of Medicine online]. 2000;75(6):607-614. Available from: University of Missouri, Kansas City, MO.
von Schacky C. n-3 fatty acids and the prevention of coronary atherosclerosis. Am J Clin Nutr. [National Library of Medicine online]. 2000;71(1 suppl):224S-227S. Available from: University of Munich, Germany.
Ernst E. Cardiovascular effects of garlic (allium sativum); a review. Pharmatherapeutica. 1987;5(2):83-89.
Wolfe MM, Lichtenstein DR, Sing G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med. 1999;340:1998-1999.
Reuters Health. Risk of aspirin for CHD prevention outweigh benefits in hypertensive men. BMJ [Medscape online] 2000;321:13-17. Accessed June 30, 2000
Loes M, Steinman D. The Aspirin Alternative:Topanga, CA: Freedom Press; June, 1999.
Windsor E, Cronheim GE. Gastro-intestinal absorption of heparin and synthetic heparinoids. Nature. 1961;190(4772):263-264.
Dow™ Chemical Company, Versene: Food-Grade EDTA. Form No. 194-1256-194XAMS:1995.
Oser, B, Oser M, Spencer HC. Safety evaluation studies of calcium EDTA. Toxicol Appl Pharmacol. 1963;5:2142-2162.
Whittaker P. Toxicological profile, current use, and regulatory issues on EDTA compounds for assessing use of sodium iron EDTA for food fortification. Regul Toxicol Pharmacol. 1993;18:419-427.
Weinberg ED. Association of iron with colorectal cancer. Biometals [National Library of Medicine online]. July, 1994;7(3):211-216. Available from: Indiana University, Bloomington, IN
Reber K, Studer A. Acceleration of the gastrointestinal absorption of heparin by calcium-binding substances. Experientia. 1963;19:141-142.
Tunis M. The inhibitory action of EDTA on erythrocyte agglutination by lectins. J Imm. 1965;95:876-879.
White JC. Effects of ethylenediamine Tetraacetic acid (EDTA) on platelet structure. Scand J Haemat. 1968;5:241-254.
Cohen P, Cooley MH, Gardner FH. Platelet preservation. III. Comparison of radioactivity yields of platelet concentrates derived from blood anticoagulated with EDTA and ACD. New Eng J Med. 1965;273:845-850.
Carpenter DG. Correction of biological aging. Rejuvenation. 1980;8:31-49.
Wartman A, Lampe TX, McDann DS, Boyle AJ. Plaque reversal with MgEDTA in experimental atherosclerosis: elastin and collagen metabolism. J Atherso Res. 1967; 7:331.
Boyle AJ, Mosher RE, McCann DS. Some in vivo effects of chelation-I: rheumatoid arthritis. J Chronic Dis. 1963;16:325-328.
Birk RE, Rupe CE. The treatment of systemic sclerosis with EDTA, pyridoxine and reserpine. Henry Ford Hospital Medical Bulletin. June, 1966;14:109-39
Leipzig LJ, Boyle AJ, McCann DS. Case histories of rheumatoid arthritis treated with sodium or magnesium EDTA. J Chronic Dis. 1970;22:553-563
Heimbach J, Rieth S, Mohamedshah F, Slesinski R, Samuel-Fernanco P, Sheehan T, Dickmann R, Borzelleca J. Safety assessment of iron EDTA [sodium iron (Fe3+) ethylenediaminetetraacetic acid]: summary of toxicological fortification and exposure data. Food and Chemical Toxicology. 2000;38:99-111
Vohra F and Kratzer, FH. Influence of various chelating agents on the availability of zinc. J. Nutrition; 82:249-56
Domingo JL. Developmental toxicity of metal chelating agents. Reprod Toxicol. 1998;12(5):499-510.
79Detergent Ingredient Review Committee. EDTA & the environment: questions & Answers. Chemical Specialties Manufacturers Association. October 1995.
Foreman H, Trujillo TT. The metabolism of C14 labeled ethylenediaminetetra-acetic acid in human beings. J Lab & Clin Med. 1954;43(4):566-571.
Foreman H, Vier M, Magee M. The metabolism of C14-labeled ethylenediamine Tetraacetic acid in the rat. J Biol Chem. 1953;203:1045.
Gordon GF. Oral chelation with EDTA. J Holis Med. Spring/Summer 1986;8(1&2):79-80.
Godal HC. The effect of EDTA on human fibrinogen and its significance for the coagulation of fibrinogen with thrombin. Scand J Clin Lab Invest. 1960;12(suppl 53):1-20.
Capet-Antonini FC. Role of calcium in the structure of fibrinogen. Biochem Biophys Acta. 1970;200:497-507.
Zucker MB. Some effects of ethylene-diaminetetraacetate (EDTA) on blood coagulation. Am J Clin Path. 1954;24:39.
Wishinsky H, Weinberg T, Prevost EM, Burgin B, Miller MJ. Ethylenediaminetetraacetic acid in the mobilization and removal of iron in a case of hemochromatosis. J Lab Clin Med. 1953;42:550.
Cohen P, Cooley MH, Gardner FH. Platelet preservation: comparison of radioactivity yields of platelet concentrates derived from blood anticoagulated with EDTA and ACD. N Engl J Med. 1965;273:845-850.
White JG. Effects of ethylenediaminetetraacetic acid (EDTA) on platelet structure. Scan J Haemat. 1968;5:241-254.
Allison F Jr, Lancaster MG. Studies on factors which influence the adhesiveness of leukocytes in vitro. Ann NY Acad Sci. 1964;116:936-944.
Forssman O, Nordqvist P. The action in vitro and in vivo of sodium Versenate on the phagocytic activity of neutrophile leukocytes. Acta Haemat. 1964;31:289-293.
Halstead BW, Rozema, TC. The Scientific Basis of EDTA Chelation Therapy. 2nd ed. Landrum, SC: TRC Publishing; 1997.
Schroeder HA. A practice method for the reduction of plasma cholesterol in man. J ChronicDis. November 1956;4(5):461-468.
Windsor E, inventor; Riker Laboratories Inc, assignee. Orally active therapeutic compositions, especially polysaccharide sulfates. US patent 3 088 868. May 7, 1968.
Zahorik R. Soap makers cure all EDTA – mystery wonder drug or hogwash? Waukegan News-Sun. April 8, 1977:18.
Bell RF, Gilliland JC, Boland JR, Sullivan BR. Effect of oral edathamil calcium-disodium on urinary and fecal lead excretion. AMA Arch Ind Health. 1956;13:366-371.
Kehoe RA. Misuse of edathamil calcium-disodium for prophylaxis of lead poisoning. JAMA Jan 22 1955;157(4):341-342.
Huff BB (ed). Calcium Disodium Versenate. Physicians’ Desk Reference. 9th ed. Oradell, NJ: Medical Economics Company, a Litton division; 1976.
Sugawara N, Sugawara C. Cadmium accumulation in organs and mortality during a continued oral uptake. Arch Toxicol. 1974;32(4):297-306.
Kelley C. Cadmium therapeutic agents. Cur Pharm Des. 1999;594):229-240.
Cotter LH. Treatment of cadmium poisoning with edathamil calcium disodium. JAMA. 1958;166(7):735-736.
Heimbach J, Rieth S, Mohamedshah F, Slesinski R, Samuel-Fernanco P, Sheehan T, et al. Safety assessment of iron EDTA [sodium iron (Fe3+) ethylenediaminetetraacetic acid]: summary of toxicological fortification and exposure data. Food Cheml Toxicol. 2000;38:99-111.
Mohamedshah F. Mineral absorption: zinc, selenium, chromium, calcium. Slide presentation at: National Institute of Health Bioavailability Conference; January 5, 2000.
Gordon GF. Oral chelation: An interview with Dr. Garry Gordon. Doctor’s Medical Library. Interview by Ron Kennedy, MD. Accessed on: October 24, 2000 www.medical-library.net/specialties/_oral_chelation.html [transcript].
Kannel WB, Hjortland MC, McNamara PM, Gordon T and The Framingham Study. Menopause and the risk of cardiovascular disease. Ann Intern Med. 1976;85:447-452.
Marlowe M, Folio R, Hall D, Errea J. Increased lead burdens and trace mineral status in mentally retarded children. J Spec Educ. 1982;16:87-99
Blumer W, Reich T. Leaded gasoline – a cause of cancer. Environ Internat. 1980;3:465-471.
Sanchez-Fructuoso AI, Torralbo A, Aroyo M, Luque M, Ruilope LM, Santos JL, et al. Occult lead intoxication as a cause of hypertension and renal failure. Nephrol Dial Transplant. 1996;11:1775—1780.
Lin JL, Lim PS. Disappearance of immune deposits with EDTA chelation therapy in a case of IgA nephropathy. Am J Nephrol. 1992:12:457-460.
Lin JL, Lim PS. Elevated lead burden in Chinese patients without occupational lead exposure. Miner Electrolyte Metab. 1992;18:1-5.
Tandon SK, Surendra S, Vinod KJ. Efficacy of combined chelation in lead intoxication. American Chemical Society. 1994;7(5).
Glotzer DE, Bauchner H. Management of childhood lead poisoning: a survery. Pediatrics. 1992;89(4):614
Olwin JH, Koppel JL. Reduction of elevated plasma lipid levels in athersclerosis following EDTA therapy. Proc Soc Exp Biol Med. 1968;128:1137-1140.
Patterson CC. Contaminated and natural lead environments of man. Arch Environ Health. 1965;11:344.
Lead: airborne lead in perspective. Paper presented: National Research Council-National Academy of Sciences, Washington, DC, 1972
Goyer RA, Rhynbe BC. Pathological effects of lead. Internat Rev Pathol. 1973;12:1.
Goyer RA, Chisolm JJ. Lead: Metallic Contaminants and Human Health. Douglas HK Lee, ed. New York: Academic Press; 1972.
Murozumi M. Chemical concentrations of pollutant lead aerosols, terrestrial dusts, and sea salts in Greenland and Antarctic snow strata. Geochem Cosmochim Acta. 1969;33:1247.
Montague P. Bad decisions again and again. Rachel’s Environment & Health Weekly. April 1997; issue 541.
Nriagu JO. The rise and fall of leaded gasoline. The Science of the Total Environment. 1990;92:13-28.
Patterson CC. Contaminated and natural lead: environments of man. Arch Environ Health. September 1965;11:344-360.
Fowler BA. Measuring Lead Exposure in Infants, Children and Other Sensitive Populations. Washington, DC: National Academy Press; 1993:14-15, 107.
Jackson R: Secondhand smoke raises stroke chances. The Arizona Republic. August 19, 1999:A10
Casdorph HR, Walker M. Toxic Metal Syndrome: How Metal Poisonings Can Affect Your Brain. Garden City Park, NY: Avery Publishing Group; 1995.
Six KM, Goyer RA. Experimental enhancement of lead toxicity by low dietary calcium. J Lab Clin Med. 1970;76:933.
Quarterman J. The influence of dietary calcium and phosphate on lead metabolism. Trace Substances in Environmental Health-VII. Hemphill DD, ed. St. Louis: University of Missouri Press;1973;347
Kopito L. Chronic plumbism in children. JAMA. 1969;209(2)
Schroder HA. The Poisons Around Us. Bloomington, IN: Indiana Univeristy Press; 1974:49.
Sugawara N, Sugawara C. Cadmium accumulation in organs and mortality during a continued oral uptake. Arch Toxicol. 1974;32(4):297-306.
Schroeder HA. Renal cadmium and essential hypertension. JAMA. 1964;187(5):359.
Fox MRS: Effect of essential minerals on cadmium toxicity: A review. Food Science. 1974;2:321-324
Nordberg, GF. Effects of long-term cadmium exposure on the seminal vesicles of mice. J Reprod Fertil. 1975;45(1):165-168.
Rifat, SL, Eastwood MR, Crapper-McLaughlan DR, Corey PN. Effect of exposue of miners to aluminum powder. The Lancet. November 10, 1990;336:1162-65.
Perl DP, Good PF. The association of aluminum, Alzheimer’s disease and neurofibrillary tangles. J Neural Transm. 1987;24(suppl):205-211.
Crapper-McLaughlan DR, McLachlan DC, Krishnan B, Krishnan SS, Dalton AJ, Steele JC. Aluminium and calcium in soil and food from Guam, Palau and Jamaica: implications for amyotrophic lateral sclerosis and Parkinsonism-dementia syndromes of Guam. Brain. 1989;112:45-53.
Bjorksten J: The crosslinkage theory or aging. J Amer Geriatrics Soc. 1968;16(4):408-42.
Hamilton EI: Aluminum and Alzheimer’s disease-a comment. Sci Total Environ. 1982;25:87-91.
Eggleston D, Nylander M. Correlation of dental amalgam with mercury in brain tissue. Res Educ. December, 1987;56(6):704-707.
Nylander M, Friberg L, Lind B. Mercury concentrations in human brain and kidneys in relation to exposure from dental amalgam fillings. Swed Dent J. 1987;11:179-187
Hemenway C: Amalgam declared dangerous. Dent Today. December 10, 1989.
Denton S: The mercury coverup. Health Consciousness Magazine. June, 1989;1-6.
Clarkson TW, Friberg L, Hursh J, Nylander M. Biological Monitoring of Toxic Metals. New York City: Plenum Press;1988.
Nolan KR. Copper toxicity syndrome. J Orthomol Psychiatr. 1983;12(4):270-282.
Crapper-McLachlan DR, Dalton AJ. Alterations in short-term retention, conditioned avoidance response acquisition and motivation following aluminimum-induced neuro-fibrillary degeneration. Physiol Behav. 1973;10:925-933.
Crapper-McLachlan DR, Tomko GJ. Neuronal correlates of an encephalopathy associated with aluminum neurofibrillary degeneration. Brain Res 1975;97:253-264.
Crapper-McLachlan DR, DeBoni U. Aluminum in human brain disease—an overview. Neurotoxicology. 1980;1:3-16.
Crapper-McLachlan DR, VanBerkum MFA. Aluminum: a role in degenerative brain disease associated with neurofibrillary degeneration. In: Swaab DF, Fliers E, Mirmiran M, VanGool, WA, VanHaaren F, eds. Progress in Brain Research. Vol 70. Amsterdam: Elsevier Science Publishers; 1986:399-409.
Hahn LJ, Kloiber R, Vimy MJ, et al. Dental ‘silver’ tooth fillings: a source of mercury exposure revealed by whole-body image scan and tissue analysis. FASEB J, 1989;3:2641-2644.
Bjorklund G. Mercury as a potential source for the etiology of Alzheimer’s disease. Trace Elements Med. 1991;8(4):208.
Kahn Van N. Heavy metal poisoning: mercury and lead. Ann Init Med, 1972;76:779-792.
Peterson CM, Stormont RT. Misuse of edathamil calcium-disodium for prophylaxis of lead poisoning. JAMA. 1955;157(4):341-342.
Clarke NE, Clarke CN, Mosher RE. The in vivo dissolution of metastatic calcium: an approach to atherosclerosis. Am J Med Sci. 1955;229:142-149.
Clarke NE, Clarke CN, Mosher RE. The in vivo dissolution of metastatic calcium: an approach to atherosclerosis. Am J Med Sci. 1955;229:142-149.
Clarke NE Sr: Atherosclerosis, occlusive vascular disease and EDTA. AM J Cardiol. 1960;6:233-236.
Rutter M, Jones RR, eds. Lead Versus Health: Sources and Effects of Low Level Lead Exposure. Chichester, New York, Brisbane, Toronto

I spent a lot of time and energy as co-author of the new book Detox with Oral Chelation. Now that I have this book in every bookstore across the country I hope someday you will purchase a copy; Amazon has it for $12.97. Then try to be familiar with the important research I have incorporated in that book. With ZEOGOLD, which takes oral detoxification to even a higher level of efficacy, I hope that all FACT members will try to become familiar with the proof that you and all your patients are very toxic and there is no way to wish these toxins away.

Go to my website and type in the search area The Chemicals within us from the National Geographic magazine.

Then go to www.ewg.org and see what your toxin load is IF you sent $4900 to Mt Sinai School of Medicine with 20 tubes of your blood. Everyone fails these tests and all have at least 60 serious toxins measurable in blood at all times.

We cannot hope to offer enough IV treatments to deal with the high levels of lead in the bones of every newborn, which CAL TECH has documented to be 1000 times higher than in bones of children 400 years ago.

I hope you will learn something from my recent interviews with Benny Hinn the televangelist that tells his audience that although he has helped many with healing by addressing their spiritual needs, he believes that I saved his life. These two shows will be aired on December 14th and 15th, please check the attached schedule for stations and times in your area and country.

They will cause many to become interested in my book DETOX WITH ORAL CHELATION. Please try to review my book, as I feel that practicing the advanced medicine I feel FACT is all about, we all must become environmentally informed physicians. I will probably do more shows with Benny Hinn and I hope many of you will avail yourself of the information about the level of toxins in all of us today.

I know many of you have no interest in new patients but your response in filling out the FACT referral form was incredible. Soon your referral information will be available on my newest website: www.fight4yourhealth.com and it is already found on www.lymebook.com/fight if you checked NO on the FACT referral form, which means we may post it on my public websites.

Thanks for you interest and I hope you will catch the Benny Hinn interview or see it on YOUTUBE now, as I feel many people around the world will want to be able to consult with someone who is a little bit familiar with the ideas I have expressed in that book. I hope to have every pregnant lady in the world one day on at least some detoxification whether Zeolite based or oral chelation or very high dose oral vitamin C or Fiber but we must stop the movement of toxin from mother to fetus if we are to survive. Thus I will do as many shows as possible to help spread the word and I need your support if this idea is ever to take off and change the health of our nation and the world.

Sincerely,

Garry F. Gordon MD,DO,MD(H)
President, Gordon Research Institute
www.gordonresearch.com

C1: Here is the URL to the full report. Confirms what was found in 2005.

http://www.ewg.org/files/2009-Minority-Cord-Blood-Report.pdf

Also, will it help to eliminate the debris in arthritic knees? I have started the therapy and would like to know if I should put off having an operation to “house clean” my knees to see if there is improvement from the therapy.

I would appreciate your insight on these questions.

For the peripheral neuropathy you have to take Lipoic acid, both the Thio-Gel L 1 twice daily and preferably 30 drops of Beyond Energy twice daily in the drink with 1-2 tsp of Beyond C and some Perfect Food. Then you need Beyond B-12 one twice daily, dissolve under the tongue 2 minutes and also add Beyond IGF-1, 2 sprays twice daily for some nerve growth factor.

I recommend a consultation, as there is much more like laser and magnetic healing etc to consider even if you do the surgery. It is not right to operate without first putting the body in TIP TOP shape and sometimes we avoid the surgery depending how advanced the condition is, your age and all other factors about your healing powers!

Sincerely,
Garry F. Gordon MD, DO, MD(H)

Thanks
Brad

First we turn off all inflammation of any kind that is needless and excessive when we recommend the Health Foundation RNA formula. Since this also will prevent several other inflammation related conditions I don’t worry much about its cost. Then I still like high quality Chondroitin with Glucosamine and Cosamin DS is expensive but probably worth it as there is so much junk.

Then everyone with any orthopedic issue should do the full 30 a day that is 10 tid away from meals, of Wobenzym for 1-2 months because the Rutosid acts as a Matrix Metallo Proteinase Inhibitor and an Iron chelator. The Quercetin, which is 36% of the Rutosid, has many useful features particularly when given with the Bromelain, which enhances the chance it will work. The pancreatic enzyme is never a waste of time or money and now we understand that the pancreas is involved in GAD, the Enzyme that breaks down Glutamate into GABA.

The more you learn about excitotoxins and glutamate, the more you might consider, if money was not an object, adding the Nerve Calm and Stress RNA formulas to her program. These work synergistically with the anti-inflammatory activity of the Health Foundation to hit many more inflammatory targets from VCAM and ICAM’s to Cyclo-oxygenases and IL 1 and 6 and fibrinogen etc. In fact using the big three, Stress, Nerve Calm and Health Foundation, is so effective that recently we took a 60+ year old male unable to sleep or walk due to severe gouty arthritis and in 4 days the pain was entirely controlled.

But this is only food and the entire picture will come back if they do not stay on the products. However, once things are all calmed down, the dosage frequency often can be reduced to once daily to save money, as there are only 24 ML in the bottles. All of these RNA products require generally 0.5 cc twice daily until the situation is fully controlled, then many can reduce frequency particularly if they are doing everything else.

That includes rebuilding the intestine so that there are no circulating immune complexes from food sensitivities. I have frequently described how to use the fiber product called Beyond Fiber with what will one day become known as the most powerful version of oral Vitamin C ever developed, Beyond C. Other versions that we have developed with our team will be replacing Ester C around the world. Of course, Beyond C has Ribose and the carcinogen free MSM only available from Cardinal and TMG and Bioperine that enhances absorption of all nutrients orally in it. It takes all of these and more to make this Vitamin C provide documented blood levels exceeding anything ever seen before and that permits unique tolerance to high levels of Vitamin C for most individuals.

In my case I had to get into pulsed magnetic field therapy like the Magnopro and I do sleep on the Bonlie Magnetico pad for enhanced maintenance of blood flow. I also increased detoxification from the Heavy Detox and Essential Daily Defense that I take daily along with my baths of EDTA (Beyond Clean).

I have had to deal with local infection in my knees and wound up using some German formulas intra-articularly that caused a rather severe healing crisis. Also I used local soft laser and local electrical stimulation to help with cell to cell communication (The Alpha Stim).

I am happy to have been successful in entirely restoring both of my knees, but few patients would ever put the energy and money into such a program that I developed. There are always those that will do well with just topical Zeel and or Traumeel and the effect can be enhanced by injections of these with Xylocaine into trigger areas around the knee. I could go on but this gives you some ideas to look at for any form of arthritis in any part of the body.

If your patient sustains trauma, use up to 50 Wobenzym orally a day. We do magic often with frequent administration of the RNA Health Foundation formula, which puts Vioxx and Celebrex that still have the ability to kill and only hit one form of inflammation, to shame.

We have seen athletes apply the RNA product, one or all three of those mentioned above, topically and take these drops, as often as every hour, until the pain etc is controlled. Then they use less often, not because of any side effects, but because they are expensive but they work for almost anything even after potentially disabling trauma, even fractures. I have seen all edema gone in 24-48 hours so that, for example, a new tighter fitting cast is needed.

The new Wobenzym Cream is making many patients happy with simple topical application to the affected area.

Sincerely,
Garry F. Gordon MD, DO, MD(H)

Dear Doctor:
In the future you will spend $100 a month and then pay RHEOLOGICS $50 for EACH blood viscosity test that you do. This is because when you read the books available from www.rheologics.com and ALL of the CRITICAL REFERENCES, you too will become convinced that if your blood has the same viscosity as menstruating women, you will be 99% protected. That is the only protection that counts.

Since your patients really just want to avoid heart attacks that is the bottom line testing. The treadmill or CAT studies or whatever test they fail is meant to wake them up that they MUST do something daily for life that makes sense if they do not want to join the 50% who die from strokes and heart attacks and pulmonary emboli.

The idea is that over time with enough viscosity levels, the plaque, which at least partly seems to be just callous on the lining of our blood vessels like callous forms on hands when we dig ditches with a shovel, will regress. But the blockages in many cases are also THROMBUS, which they can HELP dissolve with a therapeutic trial of say 2 months of 2000 F.U. per day of Endokinase (Nattokinase), which has been seen clinically to totally reverse a 3 day old stroke that had caused serious semi-paralysis. But it is the lifetime of NO clots that you are trying to help your patient enjoy. The repeat treadmills can be entirely great or markedly improved and people still die sudden deaths. That is why we also must ALSO take the SALMON OIL capsule found in the BC-I daily for life and that works via other vital mechanisms.

My research has caused me to conclude that the advantage of the tests is that it KEEPS patients CONCERNED enough to STAY on their program. I do not let the test push anyone into surgery, but it will guide me to push the ORAL program into HIGH AND AGGRESSIVE LEVELS with things that I really have NEVER fully gone into on my website as there is an element of individualization to my recommended protocols. However, that is because patients that contact me want to operate at a higher LEVEL of FUNCTIONING. That is where I can get aggressive with IV and ORAL programs, but to just stay alive is enough for many patients. That goal is far easier, MUCH cheaper, and is based around the now proven lowering of viscosity that Beyond Chelation Improved taken one bid provides apparently EVERYONE.

This is interesting, as we know there are at least some 40 separate diseases now described by Rodger Bick and others in the field of THROMBOSIS RESEARCH. Some of those are associated with VERY EARLY DEATH. It is my fear of those diseases, along with the cost of some $4000 to do the Big Panel that www.thrombocare.com PREFERS to do, that pushes me to add Endozym, 4 bid, or Endokinase, 1 Bid, to the MAINTENANCE program of a BC-I bid that I recommend for everyone. This unfortunately significantly increases the cost to the patient, but studies indicate that this NATTOKINASE addition MAY be helping clean off old thrombi. So even if they are not going to use Nattokinase for the LONG-TERM, which of course is the safest, the short term use of either 1000 FU bid (maintenance dose) or 2000 F.U bid (therapeutic dose) should be offered in my opinion to all cardiovascular patients. That can be obtained with 4-8 Endozym bid or 1-2 Endokinase bid.

Try to get your patients to watch for the PORTABLE CAT scans that are offered in the parking lot of big supermarkets across most states, for as little as $199. This does not pick up everything but somehow we all need something to keep us taking care of ourselves.

Thermography was the answer for my Sacramento clinic. All patients could see quantifiable changes in temperature of hands feet and face!! This made patients happy to STAY on their programs. In the future we will all do biological age determinations on our patients (see www.inner-age.com). It now costs $1750 but in the future some parts may be more affordable. This is what most patients will relate to – GETTING YOUNGER!

Sincerely,
Garry F. Gordon, MD,DO,MD(H)

NYTimes.com

February 17, 2004
VITAL SIGNS Evaluations: Routine Heart Tests Challenged
By JOHN O’NEIL

Three of the most common screening tests for heart disease should not be used unless the patients have known risk factors or symptoms, according to a statement released yesterday by the government panel responsible for reviewing research on preventive medicine.

The panel, the Preventive Services Task Force, concluded that problems associated with the procedures – electrocardiograms, stress tests and scans for calcium buildups in arteries - clearly outweigh their benefit. The statement was published in The Annals of Internal Medicine.

Dr. Paul Frame, a member of the task force and a professor of family medicine at the University of Rochester, said that all three tests missed a significant number of disorders and produced an even larger number of false alarms. Even when accurate, he said, the tests rarely provide information more useful than a review of risk factors like smoking, blood pressure, cholesterol levels and age.

Stress tests using treadmills, for instance, were based on the idea that they could identify people whose narrow arteries put them at risk for their first heart attacks. But researchers have learned that such heart attacks are caused by the sudden rupturing of plaque, and the tests cannot predict the ruptures, Dr. Frame said. "All you’re really accomplishing is that you might catch angina a little earlier," he said.

Dr. Frame said the effectiveness of the tests for people with symptoms or known risk factors remained unclear. The tests may be most useful in defining the condition of people at intermediate risk levels, he said. But for healthy people, "primary prevention through traditional risk factor reduction is much more important than screening tests," he said.

Comment:
Now an official government committee has stated that all the tests used for heart disease are USELESS in the absence of symptoms or known risk factors. Because NONE of these technologies can identify the plaque that is vulnerable to sudden rupture, our day of refocusing attention on BLOOD VISCOSITY and clotting disorder is coming!

Those tests were primarily useful to scare patients into compliance with whatever treatment program their doctor was able to sell to them. They will continue to be used in spite of this STRONG REPORT negating their value, since how else can they keep finding candidates to talk into cardiac interventional procedures, where, of course since the DIAGNOSTIC value is now been labeled as worthless, the attack on the value of those needless interventions from Bypass to Stenting cannot be far behind.

The new term Dr. Valentin Fuster, Past President of the American Heart Association and Chief of Cardiology at Mount Sinai Hospital in NYC, uses is VULNERABLE BLOOD!! That leaves the concept of vulnerable plaque and moves in the direction of NEEDING to PREVENT fatal blood clots continuously throughout the entire lifetime, and, hopefully, concurrently lowering Blood viscosity! I hope that some day the RHEOLOGICS blood viscosity testing will become as widely utilized as blood pressure testing (see www.RHEOLOGICS.com).

This article from the New York Times can be useful in helping your patients understand that they are being railroaded when they fail an ultra high speed cat scan or treadmill and get suckered into ANGIOGRAMS on which most will not do well. Yet what you see on the angiogram has little to do with functional capacity or the patients eventual demise.

Here are the key words from this beginning of the effort to tear down the walls of outdated cardiology thinking!

The panel, the Preventive Services Task Force, concluded that problems associated with the procedures  electrocardiograms, stress tests and scans for calcium buildups in arteries  clearly outweigh their benefit. The statement was published in The Annals of Internal Medicine."

These tests have usefulness in my practice since most patients will not spend $105 a month to be on Beyond Chelation Improved until they are frightened into doing something by their Cardiologist. Thus I do not mind the use of these tests except for the havoc that they bring so needlessly to many patients lives. Of course, some die as a result of the surgery they are pushed into that they never needed and that today still has no real documentation in most cases of significant enough benefit to outweigh the proven risks. Some Endokinase and Beyond Chelation permits a high level of functioning for most patients, even if they do not take the IV chelation that makes it all work so much better and faster, particularly now that so many are using the rapidly administered IV of Calcium EDTA.

Garry F. Gordon MD, DO, MD(H)

Dear Doctor:

I believe that some compounding pharmacist somewhere will make you something like Apo A1 of IV HDL. We also have some who are making similar claims for products like Plaquex Therapy; Plaquex is a mix of essential phospholipids derived from soybeans. Some are even claiming that EDTA specially treated, as a liposome to enhance its absorption with what are being called Essential Phospholipids, will work in a similar if not even more dramatic fashion. I view most of this as HYPE, because MANY treatments provide short-term benefits, but I think patients want LONG TERM ASSURANCES that they are going to be free of heart attacks and strokes for YEARS to come.

I consider these products to be unproven and a bit pricey and I have not seen such dramatic results as are being claimed by promoters although there are useful things to consider here. However, give patients a choice between spending money on a new experimental treatment that might slightly lower plaque on their arteries or my approach of long term, affordably, safely LOWERING BLOOD VISCOSITY. I believe that what I have developed and discuss here is a program that to date has NOT BEEN ASSOCIATED WITH A SINGLE ACUTE MI OR STROKE, that carries NO RISK, and is AFFORDABLE for the long run. I doubt that most of our patients are that focused on plaque reversal since we now know that you cannot even visualize with today’s technology the vulnerable plaque that is associated with your SUDDEN DEMISE so what test are we doing to REALLY DIMINISH THE INCIDENCE OF DEATH!

Furthermore, significant plaque in most blood vessels is generally associated with, unfortunately, largely invisible but totally effective collateral circulation. Thus staying alive is my focus, not a cosmetic reversal of some plaque that may have little to do with when the patient dies. Thus do we really want to focus primarily on plaque reversal for the short term, or for most patients should we not focus first and foremost on LONG TERM SURVIVAL OF EVERY ONE OF OUR PATIENTS.

I cannot see how injectable Apo A1 will be on board to protect your patient from their vulnerable plaque (or now Dr. Valentin Fuster has renamed the entire issue as VULNERABLE BLOOD)! How will spending some of your patient’s time and money on something that I believe some compounding pharmacist will be able to make for you, the correct course of action for MOST of the people that we see? Most will be happy to be symptom-free, which I have not failed to achieve in a patient using my programs outlined here in years.

Then once symptom free, WE STILL have to warn them that people die of acute MIs even with perfectly clean arteries. Thus, I believe, that ONLY by keeping your patients on MAGNESIUM and ESSENTIAL FATTY ACIDS and ANTIOXIDANTS and safe, affordable, anticoagulation with detoxification (ESSENTIAL DAILY DEFENSE) are we REALLY doing what is in the best interest of most of our patients. In essence, I believe that my program armorizes and thus insures patients against dying of the spasm, clot, and/or electrical misfiring that leads to death. Equating plaque reversal with those important goals is likely to prove fruitless. Most patients just want to live a few more years and I find that in the past 19 years now, nothing has empowered me to offer this assurance as much as my successful experience with Dr. Lester Morrison’s over $10 million of anticoagulation research. All of this came to be known as BEYOND CHELATION (previously EDD was known as Cardioguard, until Squibb sued saying it was too close to CORGUARD- their product).

It happens that if you read the book by Dr. Ken Kensey, Cardiologist, and President of RHEOLOGICS, and focus ON THE REFERENCES in his books, YOU will become convinced, as I have become, that THE MOST IMPORTANT news in cardiology is that you can now accurately measure blood viscosity. And we have a safe, affordable, nutritionally based program that to date has not failed to show an average of 30% lowering of blood viscosity in anyone. That makes your patients as protected against heart attacks as menstruating females are!! THIS IS NEWS and it works and we have good reason to believe that since plaque is nothing but callous, that overtime all plaque will start to reverse ON ITS OWN. So you merely offer your patients Beyond Chelation Improved and for good measure add the strongest Nattokinase on the market, ENDOKINASE, 1-2 cap bid (provides 1000 F.U. per cap).

Sincerely,
Garry F. Gordon, MD,DO,MD(H)

I lost all my arm veins when I took over 60 IV peroxide therapies. I love oxidative therapies or I would not be on the board of the International Oxidative Medicine Association founded by Dr. Charles Farr MD PHD.

I have personally chosen to try to move all of my colleagues AWAY from PEROXIDE and into HIGH DOSE VITAMIN C therapy. I do not like complications. I am convinced that we probably would be better off if we will all learn how to USE ENOUGH ORAL AND IV Vitamin C CONCURRENTLY to get our patients well, no matter what their total body pathogen burden is, without relying too much on IV peroxide. The new well tolerated oral form of Vitamin C (Beyond C) provides proven higher blood levels of Vitamin C than we have ever been able to maintain prior to this. Use it along with the knowledge of just HOW MUCH IV VITAMIN C you really need for certain conditions. Please order the book on Vitamin C and Infections by Tom Levy and the tapes by Dr. Riordan to learn all this. Remember to keep the blood level of Vitamin C between IV’s if you expect to deal with serious infections. ONLY Beyond C allows virtually everyone to tolerate 15-40 GRAMS ORALLY EACH DAY without disabling cramps and diarrhea.

I do medical and legal consulting and have been involved in cases where the
doctor is being sued over IV peroxide and the task we have in defending H202 is difficult. The FDA wants its use stopped.

I personally prefer Ultraviolet blood irradiation and the concurrent use of ozone, which gives me all the benefits without losing my veins. I have given thousands of IV peroxide treatments and wound up adding DMSO to them routinely to try to minimize the adverse effect of blood vessels, which clearly lack catalase and thus cannot deal effectively with H202.

We health professionals doing INVASIVE alternative procedures need to
carefully review our informed consent procedures and realize that when we enter a vein with medication, there are MANY things that can and will go wrong.

I assure you the VEIN was irritated and the list of things from Physical Therapy, magnetic, electrical, topical DMSA and homeopathics that I have tried to handle these post H202 infusions is long and NOTHING worked always. But try enough things and the patient will get relief and it will finally go away.

Use this to imagine what if this was a nasty patient who happened that day to be insulted by one of your staff who was having a bad day. Then try to think what you want to have in your chart should the attorney for the patient calls.

Sincerely,
Garry F. Gordon, MD,DO,MD(H)

[Mercury, fish, fish oil and the risk of cardiovascular disease. ]
[Article in Norwegian]

BACKGROUND:
Several clinical studies have documented that intake of fish may reduce mortality from coronary heart disease, and two epidemiological investigations have shown a 50 % reduction in the incidence of sudden death and of "primary cardiac arrest" in subjects eating fish. However, in some studies no beneficial effects of fish intake on coronary heart disease could be found; one Finnish study even found a positive correlation between intake of freshwater fish and coronary heart disease. One possible explanation for
this paradox could be a high content of mercury in fish.

MATERIAL AND METHODS:
We have studied the relevant literature describing beneficial, less beneficial and negative effects of fish intake on the development of coronary heart disease. Furthermore, we have studied reports that mercury may have properties that enhance the development of coronary heart disease.

RESULTS AND INTERPRETATION:
Several studies have shown an inverse correlation between omega-3 fatty acids from fish in serum/adipose tissue and coronary heart disease. However, a high content of mercury in hair/toe nail had a negative effect, and in one study the odds ratio for myocardial infarction in those with the highest content of mercury was 2.16. A positive correlation between mercury in hair and the progression of carotid atherosclerosis has been found. Intake of fish is a major source of exposure to mercury, and a high content of mercury probably inhibits the beneficial effects of omega-3 fatty acids on the development of coronary artery
disease.

Calcification

Not all calcification is due to imbalances in calcium transport, storage, excess serum or dietary levels, etc. Only calcium salts "deposit" or precipitate in tissues, not ionic calcium. Ionic calcium is essential to life, and a very large array of cellular and body functions. Pulsed and static magnetic fields are used industrially to prevent "slaking" or precipitation of calcium salts, also to prevent plaque formation in the mouth – see www.hydrofloss.com.

Breast cancer micro-calcifications may be caused by nano-bacteria (NB) and not aberrations in calcium mechanics. NB are implicated in ovarian cancer and kidney stones. Below is some info on NB’s. NB’s cloak themselves in calcium shells for whatever reasons, but may be cancer promoters/initiators, even so. Dental plaque may also be an NB problem. A wider PubMed/Medline search is needed to really gain an understanding of the current knowledge, yet very limited, on these microbes. I’m sure we will grow in amazement over time at how much harm they might cause.

Dear Doctors:
I have been disappointed in what I felt was the initial hype surrounding nanobacteria. I was told that the antibiotic treatment was without fail removing the calcium from the coronary vessels when used along with the EDTA suppositories. This clearly is not the case. I am open, however, to any infection theory as I have tons of information that total body pathogen burden is a MAJOR risk factor in virtually all chronic health problems. I do not care if these are called HHV6 or Lyme or whatever your focus.

I have proof that treating these infections with the new RNA based products permits release of toxic metals in very significant quantities in urine and feces in autistic children. Some release is associated with the clearing in a body with Measles, and more with separate treatment to help later deal with Mumps and even more then when we lower the total body burden of residual Rubella.

Then, we see more dumps of toxic heavy metals when we later deal separately with other infection issues such as strep, herpes, HHV6. Since each of those common infections are associated with the releases of DIFFERENT metals, sometimes Aluminum another time Antimony or Cadmium or Lead or Mercury, then it stands to reason that infections do tie up metals. Nanobacteria is reasonably one of these infections and it may prefer calcium to lead or mercury.

Since some of these infections are retrovirus we then find these metals are incorporated into DNA intracellularly, making chelation a VERY INEXACT SCIENCE. I hope all who read this never make the serious mistake of stating to any patient that their problem has nothing to do with heavy metals based on negative response to provoked urine and or fecal testing. Those doctors may have to later eat those words. We do not have the slightest clue yet about the kinetics of heavy metal release from the body, we are all still in kindergarten and we need to remain very humble as we go forth in looking at what is always an elephant but we are seeing only a part of this elephant at any one time!

I am pleased to have Dr. Pawluk’s contributions to this discussion group as I consider him to be an authority on the use of pulsed magnetic field therapy and I believe that devices such as the OMT and QRS will make another significant contribution to our patients’ health in many ways. Clearly we see improvement in some of these patients with osteoporosis with remineralization of bone. Anything that is able to do this should also be useful in improving ENERGY in the body that permits all functions, hormonal etc, to operate more efficiently. Pathologic calcification is part of aging and also may be tissue specific. As he says, in some, nanobacteria may be an important part of the problem.

So far, I have helped all but one patient turn around sometimes frightening levels of coronary calcification, but it has always required me to do everything to promote optimal health everywhere. I use things like Vit D, boron, Vitamin K2, rebounding exercises on mini trampoline, some sun exposure, some needed IV ozone-with ultraviolet radiation, which is my favorite way of lowering the total body burden to many of these infections, but that is not widely available.

I will be teaching at the AUTISM training course in Boston August 14-15 more about how I use the new line of RNA products to induce the release of these toxic heavy metals from the body. It is almost like inducing a HOMEOPATHIC healing crisis to enable the body to clear out one by one the residual levels of these various infections.

Sincerely,
Garry F. Gordon, MD,DO,MD(H)

Right/Left Brain Balance in Communications

Hi Garry and Chelation Discussion Group,

In a recent letter the doctor refers to treating diseases. This is most common in the majority of communications I receive from not only the CDG members but from many others — received a letter this morning from a nutraceuticals company with the same expression.

My life’s purpose is to raise health consciousness — awareness, understanding, and knowledge and to teach UCLA = UNCONDITIONAL LOVE AND ACCEPTANCE OF SELF AND OTHERS. On an inter/national basis I actively did for fifteen years with HEALTH CONSCIOUSNESS magazine that was circulated in thirty-two countries. I feel it is important to continually develop a balance between the right and left hemispheres of the brain. In my days of the 1950s medical school taught me mainly the science of medicine and little to no emphasis was placed upon the art. I was taught to make and treat the diagnosis. Perhaps many of you have been in the same boat? Perhaps you are changing your course to be an even better, physician/clinician and human being?

So, here is my suggestion to those applicable. You may choose to show greater respect and to change your communications to first mentioning that I am treating a patient with a specific disease like herpes, or with cancer.